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D-Glutamic acid-adding enzyme (MurD) catalyses the essential addition of D-glutamic acid to the cyto-
plasmic peptidoglycan precursor UDP-N-acetylmuramoyl-L-alanine, and as such it represents an
important antibacterial drug-discovery target enzyme. Based on a series of naphthalene-N-sulfonyl-D-
Glu derivatives synthesised recently, we synthesised two series of new, optimised sulfonamide inhibitors
of MurD that incorporate rigidiﬁed mimetics of D-Glu. The compounds that contained either constrained
D-Glu or related rigid D-Glu mimetics showed signiﬁcantly better inhibitory activities than the parent
compounds, thereby conﬁrming the advantage of molecular rigidisation in the design of MurD inhibitors.
The binding modes of the best inhibitors were examined with high-resolution NMR spectroscopy and
X-ray crystallography. We have solved a new crystal structure of the complex of MurD with an inhibitor
bearing a 4-aminocyclohexane-1,3-dicarboxyl moiety. These data provide an additional step towards the
development of sulfonamide inhibitors with potential antibacterial activities.
 2011 Elsevier Masson SAS. All rights reserved.1. Introduction
The increasing resistance of Gram-positive and Gram-negative
pathogens that cause severe infections in communities and in
hospitals and all over the World constitutes a serious public health
threat [1]. As drug-resistant infections and relatedmorbidity are on
the rise, there is an urgent need for the discovery and development
of novel antibacterial agents that are directed against previously
unexploited targets [2]. Peptidoglycan is an essential cell-wall
polymer that is unique to prokaryotic cells, and it thus fulﬁls the
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son SAS. All rights reserved.ﬂexibility and strength required for bacterial cells to grow and
divide, as well as protection against osmotic pressure [3]; it is
therefore an important target in antibiotic research [4].
The intracellular assembly of the peptide stem of peptidoglycan
is ensured by a series of four essential enzymes, known as the Mur
ligases (MurC to MurF). These provide the consecutive additions of
L-alanine (MurC), D-glutamic acid (MurD), a diamino acid, which is
generally meso-diaminopimelic acid or L-lysine (MurE), and the
dipeptide D-Ala-D-Ala (MurF) onto the D-lactoyl group of UDP-N-
acetylmuramic acid (UDP-MurNAc) [4]. These ligase enzymes thus
catalyse the formation of peptide bonds between UDP-precursors
and amino acids or dipeptide. The reactions start by phosphoryla-
tion of the terminal carboxyl group of the nucleotide precursor, to
form an acylphosphate, which is then attacked by the aminemoiety
of the incoming amino acid or dipeptide. The high energy tetra-
hedral intermediate that is produced subsequently collapses, to
yield an amide or a peptide, adenosine diphosphate (ADP), and
inorganic phosphate [5]. A divalent cation, as Mg2þ or Mn2þ, is
essential for the reaction. Of note, sequence alignments of Mur
ligase orthologues and paralogues show relatively low overall
I. Sosic et al. / European Journal of Medicinal Chemistry 46 (2011) 2880e2894 2881homologies, with the exception of the residues that comprise their
active sites. The ATP-binding pocket appears to be well conserved
in particular, throughout this enzyme family [6e9].
Crystal structures of these Mur ligases have shown that
they have similar three-dimensional structures in three domains:
the N-terminal domain involved in the binding of the UDP-
precursor, the central domain involved in the binding of ATP, and
the C-terminal domain involved in the binding of the amino acid or
dipeptide. While the topologies of the central and C-terminal
domains are similar among theMur ligases, those of the N-terminal
domains show differences, with MurC and MurD more closely
related to each other than to MurE and MurF. These differences are
related to the lengths of the UDP-precursor substrates [10].
Furthermore, the open and closed X-ray structures of free and
complexed MurD [11e13] and MurF [14,15] show that the C-
terminal domain undergoes substantial conformational changes
upon substrate or inhibitor binding [16].
The main focus of our research has been MurD, the second
enzyme in the series of Mur ligases. It catalyses the formation of the
peptide bond between UDP-N-acetylmuramoyl-L-alanine (UMA)
and D-Glu. The importance of this enzyme as a potential drug target
has resulted in several attempts to design inhibitors of MurD
over the last 15 years. For instance, the effects of various analogues
of D-Glu onMurD from Escherichia coli have been studied, and some
alternative substrates were described [17]. Many phosphonic acids
and phosphinates (e.g., Fig. 1, compound 1) have been developed as
substrate analogues and tetrahedral transition-state analogue
inhibitors of MurD, respectively [18e23]. Several inhibitors were
also identiﬁed from a library of N-acyl-D-Glu derivatives; those
containing an indole moiety appeared to be of special interest [24].
A series of compounds with an N-acylhydrazone scaffold was
synthesised and compound 2 (Fig. 1) was identiﬁed as the most
potent inhibitor [25]. Using de-novo structure-based molecular
design, a series of macrocyclic inhibitors 3 (Fig. 1) was developed,
which showed IC50 values in the low micromolar range [26].
Peptide inhibitors of MurD from Pseudomonas aeruginosa were
obtained by screening of phage display libraries using competitive
biopanning approaches, with the best IC50 value obtained of 4 mM
[27]. Pyrazole derivatives [28] and pulvinones [29] have beenFig. 1. Structural formulae of soreported to be potential inhibitors of MurBeMurD and Mur-
AeMurD, respectively. An example of the computational methods
that have provided four novel MurD inhibitors (e.g., Fig. 1,
compound 4) was the approach of virtual screening and subse-
quent in-vitro biochemical evaluation of the best-ranked
compounds [30]. Using a new high-throughput ﬂuorimetric assay,
a focused library of around 1000 compounds was also screened for
inhibition of MurD, and a novel inhibitor belonging to a new
structural class was discovered (i.e., Fig. 1, compound 5) [31].
Recently, the high-resolution co-crystal structures of MurDwith
N-sulfonyl-L-Glu (9) (IC50 ¼ 710 mM) and N-sulfonyl-D-Glu (10)
(IC50 ¼ 280 mM) (Fig. 1) were reported. The binding modes of these
inhibitors were also characterised according to their enzyme
kinetics. Here, the conﬁguration of the glutamic acid moiety of this
type of inhibitor did not need to be D, since the N-sulfonyl-L-Glu
analogue 9 can bind to the D-Glu-binding site in a similar manner to
the D-Glu counterpart 10, and it was only 4-fold less potent [32].
Interestingly, the same trend was seen with compounds 7 and 8,
which bear both the glutamic acid and 5-benzylidenerhodanine
moieties (Fig. 1) [33]. A series of naphthalene-N-sulfonyl-D-Glu
derivatives related to 10 was designed and synthesised in an
attempt to obtain improved inhibitors (Fig. 1, compound 11) and
four additional co-crystal structures were reported [34]. Further-
more, these compounds were also the subject of extensive, high-
resolution nuclear magnetic resonance (NMR) and molecular
dynamics studies, which shed additional light on the static models
obtained from the co-crystal structures [35]. Such information from
experimentally determined positions and conformations of inhib-
itors in the MurD active site provides excellent insight into the
structureeactivity relationships, and offers a solid foundation for
further development and optimisation of inhibitors from this
structural class.
In the present study, we describe our approach to the design of
a second generation of sulfonamide inhibitors of MurD that are
related to compounds 10 and 11 (Fig. 1). We optimised these
inhibitors through the rigidisation of their D-glutamic acid moiety.
As rigidisation represents an important aspect in medicinal
chemistry optimisation processes, most probably due to minimis-
ing the entropic penalty upon binding of ligands in the active site ofme MurD ligase inhibitors.
Scheme 1. Reagents and conditions: (a) Na, EtOH, toluene, 80 C; (b)
NH2OH  HCl, Na2CO3, H2O/EtOH; (c) H2, Raney-Ni, i-PrOH; (d) Benzylamine,
Na(OAc)3BH, 1,2-dichloroethane; (e) H2, Pd/C, EtOH, 20 bar.
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contribute to potentiation of the binding afﬁnities and improved
inhibitory activities of these synthesised compounds. In addition,
we present the crystal structure of a rigidiﬁed inhibitor in complex
with MurD, as well as high-resolution NMR data additionally con-
ﬁrming the binding of these novel inhibitors to the active site of
MurD.
2. Chemistry
To ﬁnd newMurD inhibitors, compounds 10 and 11 (Fig. 1) were
used as the starting points for further derivatisation and optimi-
sation. We wanted to replace the D-glutamic acid moiety of
these two compounds with different rigid fragments that would
mimic D-glutamic acid. The conformationally rigid D-Glu mimetics
were comprised of either an aromatic or an aliphatic ring, with
various polar substituents (OH, COOH, CH2COOH) at different posi-
tions of the ring. The majority of the aromatic and cyclic aliphatic
amines used (Table 1) were commercially available (compounds
12aec and 12eeh), except diethyl 4-aminocyclohexane-1,3-dicar-
boxylate (12d) and dimethyl 4-aminoisophthalate (12i). As we
wanted to cover the substitution patterns on the aliphatic and
aromatic rings as much as possible, we decided to synthesise these
two constrained D-Glumimetics. The syntheses of these two amines
are shown in Schemes 1 and 2.
The preparation of diethyl 4-oxocyclohexane-1,3-dicarboxylate
(14) was achieved by the Dieckmann cyclisation of triethyl pentane-
1,3,5-tricarboxylate (13) using sodium as the base (Scheme 1). The
desired cyclic aliphatic amine 12d was then synthesised using two
different approaches. The ﬁrst consisted of the formation of the
oxime derivative 15 that was promptly (due to instability of the
compound) reduced to 12d using Raney-Ni as a catalyst [37]. Since
the overall yield of this synthesis (16%) was not satisfactory, we also
prepared the target compound 12d by reductive amination of 14,
using benzylamine and sodium triacetoxyborohydride as the
reducing agent [38]. Despite the steric hindrance of ketone 14, the
reaction proceeded smoothly and with good yield (72%). The ﬁnal
deprotection of the amino group was achieved by catalytic hydro-
genolysis, to yield 12d. For further reactions, the 12d obtained with
this second synthetic procedure was used.
The second synthesis of the constrained Glu derivative 12d
proceeded with unexpected stereoselectivity. Even though two
chiral centres were formed during the cyclisation step to obtain the
ketone 14, the reaction proceeded diastereoselectively, and a single
pair of enantiomers was isolated, as conﬁrmed by HPLC (see
Supplementary data). Moreover, reductive amination of 14 alsoTable 1
Structures of C-protected conformationally rigid D-Glu mimetics.took place stereoselectively, and compound 16, which has three
chiral carbons (and can potentially exist in eight stereoisomeric
forms), was isolated after puriﬁcation as a single enantiomeric pair.
For both compounds (14 and 16), HPLC analysis on a high resolution
(achiral) C18 column with high efﬁciency (plate number 300,000)
gave a single symmetric peak, indicating that there were no dia-
stereoisomers. With chiral columns, two separate peaks with a 1:1
area ratio were seen, clearly demonstrating the formation of an
enantiomeric pair (see HPLC spectra in the Supplementary data).
The synthesis of aromatic amine 12i was also performed using
two different approaches. The initial step in the ﬁrst reaction
pathway was microwave-assisted copper-catalysed CeN bond
formation using 4-bromisophthalic acid and benzylamine [39]. The
carboxyl groups of the resulting compound 18 were subsequently
protected as methyl esters using thionyl chloride and MeOH. The
benzyl group of 19 was then easily removed with catalytic hydro-
genation, to obtain the aromatic amine 12i. The overall yield of this
approach was very low (13%), which was mostly due to the poor
conversion of 17 to 18 in the ﬁrst reaction step. The title 2,4-
disubstituted aniline 12i was therefore synthesised using
a different approach, starting from commercially available methyl
2-amino-5-furoate (20) and methyl acrylate, following a literature
procedure [40]. AfterDielseAlder reaction in theﬁrst step the amino-
substituted 7-oxabicyclo[2.2.1]heptene 21 was spontaneously
Scheme 2. Reagents and conditions: (a) Cu, Cu2O, K2CO3, 2-ethoxyethanol, 130 C, MW; (b) SOCl2, MeOH; (c) H2, Pd/C, MeOH; (d) toluene, 90 C; (e) BF3  OEt2, toluene, 90 C.
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and theproduct22wasused immediately for thenext step, a reaction
with BF3  Et2O in toluene at 90 C which resulted in smooth dehy-
dration and gave the 2,4-disubstituted aniline 12i in very high yield
(88%).
The rigid sulfonamide inhibitors were synthesised as shown in
Scheme 3. The 6-substituted naphthalene-2-sulfonyl chlorides (27
and 28) were prepared from sodium 6-hydroxynaphthalene
sulfonic acid (23), according to a procedure in the literature [34].
Aromatic and cyclic aliphatic amines with variously protected
carboxyl groups at different positions (Table 1, 12aei) were then
successfully reacted with these two sulfonyl chlorides, which
yielded the sulfonamides 29aei and 30aei. These esters were
subsequently deprotected with alkaline hydrolysis, to the target
compounds 31aei and 32aei (Table 2). For deprotection of the
carboxyl groups of compounds 29aei and 30aei, alkaline hydro-
lysis was applied.
3. Results and discussion
3.1. MurD inhibitory and antibacterial activities
The target compounds were tested for their inhibitory activities
on MurD from E. coli. The results were determined as residual
activities (RAs) of the enzyme in the presence of 500 mMor 1mMofScheme 3. Reagents and conditions: (a) Na, EtOH, rt; (b) for compound 25: BuBr, DMSO, ro
SOCl2, DMF, 0 C to room temp; (d) for compounds 29a, 30a and 29h, 30h: corresponding
amine, CH2Cl2, Et3N, room temp; for compounds 29f and 30f: amine 12f, THF, Et3N, room te
31aei: 1 M NaOH, dioxane, room temp; for compounds 32aei: 2 M LiOH, dioxane, room teach compound, and also as IC50 and Ki values for the most active
compounds (Table 2).
The ﬁrst series of synthesised compounds consisted of
6-butoxynaphthalene-2-sulfonamide derivatives (31ae31i). The
compounds that had only one carboxyl group, 31aec and 31e, were
not active against MurD. These data were not surprising as it is
known from previously published inhibitors that both of the
carboxyl groups of D-Glu form important interactions with the
active site of MurD [23,34]. We thus conﬁrmed that amines with
only one carboxyl group are poor mimetics of glutamic acid. As
expected, slightly better inhibition was seen with compounds 31f-
31i, which have two polar groups at various positions on the
aromatic ring. The most interesting data was from the comparison
of the inhibitory potencies of compounds 31f (RA at 500 mM, 76%)
and 31i (RA at 1 mM, 8%; IC50 ¼ 127 mM). The importance of the
carboxyl group at the para positionwith respect to the sulfonamide
moiety was evident, in comparison with the hydroxyl group. We
can see that substituents that can form additional hydrogen bonds
or charge-based interactions contribute greatly to the inhibition of
MurD.
The best inhibitors were obtained with the second series of
compounds, the [6-(4-cyano-2-ﬂuorobenzyloxy)-naphthalene-2-
sulfonamide derivatives 32ae32i]. Compounds 32a and 32c were
practically inactive. With a comparison of the residual activities of
compounds 32b (RA, 45%) and 32c (RA, 88%), it can be noted thatom temp; for compound 26: 4-cyano-2-ﬂuorobenzyl bromide, DMSO, room temp; (c)
amine, EtOH, Et3N, 55 C; for compounds 29bee, 30bee and 29g, 30g: corresponding
mp; for compounds 29i and 30i: amine 12i, CH2Cl2, py, room temp; (e) for compounds
emp.
Table 2
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Ki ¼ 5.8 mMd
a The data represent the mean values of two independent experiments. Standard deviations were within 10% of these mean values.
b Except where noted otherwise, RA was determined at 500 mM of each compound.
c RA was determined at 1 mM of each compound.
d Ki values were calculated using the ChengePrusoff equation.
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mimicking the position of the a-carboxyl group of D-glutamic acid.
The (1R,2S)-conﬁguration on the cyclohexyl ring appeared to
present a preferable spatial orientation for the carboxyl and
sulfonamide groups. Very promising MurD inhibitionwas obtained
with compound 32d, which showed an IC50 of 182 mM. This makes
compound 32d particularly interesting for further investigations, as
it is a mixture of two enantiomers. As discussed above for inter-
mediates 14 and 16, HPLC chromatograms of esters 29d and 30d,
and those of the corresponding acids 31d and 32d, showed that
these compounds were isolated as single enantiomeric pairs with
1:1 ratios of their two enantiomers (see Supplementary data).
As has been seen previously, the poor inhibitory activity of
compound 31d in comparison with 32dmight have arisen because
the p-cyano-2-ﬂuorobenzyloxy group at position 6 of the naph-
thalene ring contributes to a better afﬁnity, as the cyano group
forms additional hydrogen bonds with the MurD active site [34].
Valuable information can be obtained from the inhibition assay
results of compounds 32fei. All of these compounds were better
inhibitors than compound 11, which was our starting point. While
compounds 32feh had almost identical inhibitory activities (IC50
values between 38 and 50 mM), compound 32i exhibited 5efold
better inhibition (IC50 ¼ 8.4 mM). Again, to obtain a more potent
inhibitor, it was signiﬁcantly better with the carboxyl group posi-
tioned para with respect to the sulfonamide group rather than the
hydroxyl group.
To sum up, from the 6-butoxynaphthalene-2-sulfonamide series
of compounds (31ae31i), 31i was the most potent, with an IC50 of
127 mM. When comparing its activity with compound 10 (Fig. 1), it
can be noted that the rigidisation had here led to a more potent
inhibitor. Even better results were obtained with the second series
of compounds, which had the p-cyano-2-ﬂuorobenzyloxy side
chain (32ae32i). Compounds 32fei (IC50 values between 8.4 and
50 mM) were all more potent inhibitors than the parent D-Glu
derivative 11 (Fig. 1). We showed that the best D-Glu constrained
mimetic was the amine 12i, as it appears that the 4-amino-1,3-
dicarboxyl substitution pattern on the phenyl ring was the best for
mimicking the polar groups of glutamic acid. Compound 32i
(IC50 ¼ 8.4 mM) contained this moiety and exhibited a more than
10-fold increase in inhibitory activity when compared with
compound 11. From the results of the inhibition assays (Table 2), we
conclude that incorporation of a rigid surrogate into the D-glutamic
acid moiety can potentiate the binding afﬁnity, and thus contributeto better inhibitory activities of these synthesised molecules. This
was recently also conﬁrmed in a series of benzene-1,3-
dicarboxylate-containing compounds, which were discovered by
virtual high-throughput screening for MurD and MurE [41].
All of the compounds were tested for their in-vitro antibacterial
activity against several different Gram-negative and Gram-positive
bacterial strains. The data are given in Table S2 of the Supple-
mentary data. These compounds were unfortunately found to be
weak inhibitors of bacterial growth. This might be ascribed to their
poor penetration into the bacterial cytoplasm. Nevertheless, some
compounds showed modest antibacterial activities; e.g., 31b, 31c
and 31d against Listeria innocua, Listeria monocytogenes, Bacillus
subtilis and Enterococcus hirae, with minimal inhibitory concen-
trations (MICs) of 32 mg/mL or 64 mg/mL. Interestingly, compound
31d also moderately prevented the growth of one strain (PL1) of
inducible methicillin-resistant Staphylococcus aureus. However, as
these compounds were very poor inhibitors, if at all, of MurD, the
antibacterial activities observed were probably due to their inter-
actions with another bacterial target.
3.2. NMR
With MurD selectively labelled with 13C at the methyl groups of
Ile, Val and Leu [42], the monitoring of its 1H/13C chemical shift
changes upon binding of selected new ligands (31d, 31h, 32fei)
was performed, to support the speciﬁc action of these inhibitors
and to determine the location of the ligands in the MurD binding
site. We demonstrated that these new inhibitors bind to the active
site in a similar manner to that previously established for
compounds 10 and 11, using X-ray diffraction [32,34] and high-
resolution NMR [35]. The same methyl resonances of MurD were
affected upon binding of new ligands as observed for compounds
10 and 11. Typically pronounced effects on chemical shifts of Leu416
methyl groups were observed upon binding of inhibitors (Fig. 2).
This is a consequence of ring-current effects of the naphthalene
ring, which is in close spatial proximity to Leu416, and it indicates
the similar location of the naphthalene ring in the binding site as
for the naphthalene-N-sulfonamide-D-Glu derivatives. The signals
of these Leu416 methyl groups are the only ones that are affected
upon binding of D-glutamic acid, and they are indicative of the
location of the ligands in the D-Glu-binding pocket. The occupancy
of the uracil-binding pocket with the C6-substituent was estab-
lished through the pronounced effects on the chemical shifts of the
Fig. 2. The combined chemical shift perturbations of the Leu416 methyl group
calculated from the 1H and 13C chemical shifts in the absence and presence of the
indicated compounds at a 5:1 ligand:MurD ratio. For compounds 31d, 31h, 32f, 32g,
32h and 32i, the minimum possible chemical shift perturbation is presented, as the
signals moved to the overlapped region of the spectra at a 5:1 ligand:MurD ratio. The
chemical shift perturbations of the other Leu416 methyl group are not presented, as
the signals moved to the overlapped region of the spectra after the ﬁrst addition of the
naphthalene-N-sulfonamide derivatives.
Fig. 4. The combined chemical shift perturbations of the Ile74 d1 methyl group
calculated from the 1H and 13C chemical shifts in the absence and presence of the
indicated compounds at a 10:1 ligand:MurD ratio.
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benzyloxy)-naphthalene derivatives had greater effects on these
chemical shifts than the 6-butoxynaphthalene derivatives. A similar
differencewas seenupon thebindingof compounds10 and11,which
can be attributed to the ring-current effects of the arylalkyloxy
substituent (Figs. 3 and 4). The side chains of Leu57 and Ile74
constitute the hydrophobic environment of the uracil-binding
pocket and are in close spatial proximity to the C6-substituent of
the naphthalene-N-sulfonamide-D-Glu derivatives [32,34,35].
3.3. Crystal structure of MurD in complex with compound 32d
To additionally conﬁrm the atomic detail of the binding mode of
these inhibitors within the MurD active site, the crystal structure of
the complex between MurD and inhibitor 32d was solved to high
resolution (Fig. 5). Compound 32dwas obtained as amixture of two
enantiomers (see above), and the mixture was soaked in crystals of
MurD (see Experimental Section). The data was collected at the
European Synchrotron Radiation Facility (Grenoble, France), and
the structure of the complex was solved by molecular replacement
using the structure of the apo form of MurD as the searchmodel. Of
note, only one stereoisomer was seen in the co-crystal structure.Fig. 3. The combined chemical shift perturbations of the Leu57 methyl groups
calculated from the 1H and 13C chemical shifts in the absence and presence of the
indicated compounds at a 10:1 ligand:MurD ratio.The absolute conﬁguration of the crystallised compound was
(1R,3R,4S). This is in agreement with the inhibition assay results
that were obtained with compounds 32b and 32c, as compound
32b, which has the (1R,2S)-absolute conﬁguration, showed better
inhibitory activity (N.B., compliance with the IUPAC nomenclature
rules alters the numbering priorities when an additional carboxyl
group is on the ring). The carboxyl groups at positions 1 and 3 of the
rigid cyclohexyl mimetic of D-glutamic acid occupy exactly the
same position as the carboxyl groups of D-glutamic acid of previ-
ously described inhibitors [32,34] and of the product UDP-MurNAc-
L-Ala-D-Glu [11]. The carboxyl group at position 3 of the cyclohexyl
ring of the inhibitor forms a charge-based interaction with Nx of
Lys348, and is additionally hydrogen-bonded with a conserved
water molecule, W38, which is further hydrogen-bonded to Og of
Thr321 and the carboxyl group of Asp182. The carboxyl group at
position 1 of the cyclohexyl ring is held in place by hydrogen bonds
with Og of Ser415 and the backbone nitrogen of Phe422. The
sulfonic group also contributes to the recognition in the active site
by making hydrogen bonds with His183 and water molecules
W183, W242 and W415; W183 and W242 further interact with
the side-chain carboxyl of Asp346. The naphthalene ring of theFig. 5. Binding mode of compound 32d (magenta) in the active site of E. coli MurD
(interactions with conserved water molecules are not shown). The superposition with
compound 11 (cyan) is also shown. (For interpretation of the references to colour in
this ﬁgure legend, the reader is referred to the web version of this article.)
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and Ca of Gly73. The functional group at position 6 of the naph-
thalene ring extends into the uracil-binding pocket. The oxygen at
position 6 interacted with Og of Ser71, and the cyano group at
position 4 of the phenyl ring is hydrogen-bonded to Ob of Thr36.
The phenyl ring makes interplane stacking interactions with Asp35
and Arg37.
4. Conclusions
We have synthesised two series of new, optimised sulfonamide
inhibitors of MurD that incorporate rigidiﬁed mimetics of D-Glu.
These compounds showed better inhibitory activities than the
starting compounds, thereby conﬁrming the advantage of such
constrained glutamic acid analogues. Additionally, we solved a new
crystal structure of the inhibitor with a 4-aminocyclohexane-1,3-
dicarboxyl moiety in complex with MurD. We have described
several possible rigid surrogates of D-Glu that can be used for
further optimisation of inhibitors of MurD. These data provide
another step forwards towards the development of sulfonamide
inhibitors with antibacterial activities.
5. Experimental section
5.1. Inhibition assay
The compounds were tested for inhibition of addition of D-[14C]-
Glu to UMA catalysed by MurD from E. coli [43] using a mixture
(ﬁnal volume, 50 mL) containing 0.1 M TriseHCl, pH 8.6, 5 mM
MgCl2, 25 mM UDP-MurNAc-L-Ala, 25 mM D-[14C]-Glu (50,000 cpm),
5% (v/v) DMSO, 30 mM Tween 20, puriﬁed MurD (diluted in 20 mM
potassium phosphate, pH 7.0, 1 mM dithiothreitol, 1 mg/mL BSA),
and 500 mM or 1 mM of each test compound (at these concentra-
tions, the compounds were soluble in the assay mixture containing
DMSO). The enzyme concentration in the ﬁnal mixture was 0.5 nM.
The mixture was incubated at 37 C for 30 min, and the reaction
was stopped by adding 10 mL glacial acetic acid. The resulting
mixture was lyophilised and taken up in water (ca. 10 ml). The
radioactive substrate and product were separated by TLC on LK6D
silica gel plates (Whatman), which were developed in 1-propanol/
ammonium hydroxide/water, 6/3/1 (v/v), and quantiﬁed with
a radioactivity scanner (model Multi-Tracemaster LB285, Berthold-
France, Thoiry, France). Residual activity was calculated with
respect to a similar assay without the inhibitors. The data are
expressed as means of duplicate determinations, and the standard
deviations were within 10% of the given values. All enzyme assays
were performed at the initial velocity conditions (linearity ensured
until 30 min). The IC50 values were calculated from the ﬁtted
regression equation using the logit-log plot. Ki values for the most
potent compounds were calculated using the ChengePrusoff
equation since it is known from X-ray and NMR experiments that
inhibitors are competitive towards D-Glu (Km value for D-Glu:
55 mM).
5.2. Antimicrobial activity evaluation
Tests for antimicrobial activities were carried out using micro-
titration plates, in 200 ml (ﬁnal volume) of MüellereHinton broth
(MHB), following the procedures recommended by the European
Committee for Antimicrobial Susceptibility Testing [44] and the
Clinical Laboratory Standards Institute [45]. The compounds were
dissolved in 100% DMF and then diluted 50-fold in MHB, just before
use. Inoculums were prepared for each strain, with resuspended
isolated colonies from 18 h cultured plates. Equivalents of 0.5
MacFarland turbidity standard (approximately 1.108 CFU/ml) wereprepared in saline solution (0.085% NaCl) and then diluted 200-fold
in MBH (initial population). The MICs were determined as the
lowest dilutions of the products showing no visual turbidity.
Bacterial strains (Supplementary data, Table S2) were purchased
from the BCCM/LMG Laboratorium voor Microbiologie, Universiteit
Gent (UGent), Belgium.
5.3. NMR spectroscopy
The 1H/13C HSQC [46] spectrawere recorded at 25 C on a Varian
DirectDrive 800MHz spectrometer equippedwith a Cryoprobe. The
pulse sequence provided in the Varian BioPack library of pulse
programmes was used. The NMR samples were prepared in 90%
H2O/10% DMSO-d6 buffer containing 20 mM HEPES, 7 mM
(NH4)2SO4, 3.5 mM MgCl2, 0.3 mM dithiothreitol, and 0.4 mM ATP,
pH 7.2. The MurD selectively labelled with 13C at the methyl groups
of Ile (d1 only), Val and Leu was at 0.07 mM. The MurD was titrated
by the ligands for MurD:ligandmolar ratios of 0.5,1, 2, 5 and 10. The
spectra were acquired with 1024 data points in t2, 32 scans, 64
complex points in t1, and a relaxation delay of 1 s. The 1H and 13C
sweep widths were 9470 and 3340 Hz, respectively. The spectra
were processed with the NMRPipe software [47] and analysed with
the Sparky software [48]. The spectra were zero-ﬁlled twice and
apodised with a squared sine bell function shifted by p/2 in both
dimensions, using linear prediction of the data in the incremented
dimension. The combined chemical shift changes, which include
information of both involved nuclei and are more convenient to
analyze 1H/13C HSQC data, were used [49]. The combined chemical
shift changes Dd1H/13C were calculated from 1H to 13C chemical
shift changes using the equation: Dd1H/13C ¼ ((Dd1H)2
þ (0.252  Dd13C)2)1/2 where 0.252 is the weighting factorwwhich
accounts for differences in sensitivity of 1H and 13C resonances [50].
It is expressed as: w ¼ jg13Cj/jg1Hj where g13C and g1H are magne-
togyric ratios of 13C nucleus and the proton, respectively [49].
5.4. Crystallisation, preparation of the inhibitor complex, and data
collection
Crystals of conformationally closed MurD ligase were obtained
by co-crystallising MurD at 293 K with UMA and a non-
hydrolysable analogue of ATP (AMP-PNP) [11,12,32]. The crystals
were obtained using the vapour-diffusion method and a hanging-
drop system in Linbro plates, by mixing drops of 2 mL of MurD
solution (3 mg/mL puriﬁed enzyme, 20 mMHEPES, pH 7.4, 200 mM
NaCl, 5 mM dithiothreitol, 1 mM UMA and 5 mM AMP-PNP) and
2 mL of reservoir solution (0.1 M HEPES, pH 7.5, 1.9 M ammonium
sulphate, 7% (w/v) PEG 400 and 50 mM NaCl). The crystals were
grown over 6 days, and subsequently incubated with 1.5 mM
compound 32d in 2% (v/v) DMSO for 36 h. After these 36 h of
soaking, the crystals were rapidly frozen in liquid nitrogen, using
Paratone oil as a cryoprotectant. The dataset was collected with the
ID14-EH2 beamline at the European Synchrotron Radiation Facility
(Grenoble, France).
5.5. Materials and methods. Chemistry
Reagents and solvents were obtained from commercial sources
(Fluka, SigmaeAldrich, Acros Organics, Alfa Aesar, Fluorochem).
Solvents were distilled before use, while the other chemicals were
used as received. All of the reactions were carried out under an
argon atmosphere with magnetic stirring, unless otherwise stated.
Microwave-assisted reactions were performed using a focused
microwave reactor (Discover, CEM Corporation, Matthews, NC,
USA). Hydrogenation reactions were performed using a Parr 4842
hydrogenation apparatus. Analytical TLC was performed on Merck
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were visualised under UV light and/or stained with the relevant
reagent. Column chromatography was performed on Merck silica
gel 60 (mesh 70-230), using the indicated solvents. Yields refer to
the puriﬁed products, and they were not optimised. All of the
melting points were determined on a Reichert hot-stage apparatus,
and are uncorrected. Optical rotation was measured on a Per-
kineElmer 1241 MC polarimeter. 1H NMR spectrawere recorded on
a Bruker Avance 300 DPX spectrometer at 302 K, and are reported
in ppm using tetramethylsilane or solvent as an internal standard
(DMSO-d6 at 2.50 ppm, CDCl3 at 7.26 ppm). The coupling constants
(J) are given in Hz, and the splitting patterns are designated as: s,
singlet; bs, broad singlet; d, doublet; dd, double doublet; t, triplet;
and m, multiplet. 13C NMR spectra were recorded on a Bruker
Avance 400 DPX spectrometer at 302 K, and are reported in ppm
using solvent as an internal standard (DMSO-d6 at 39.5 ppm, CDCl3
at 77.0 ppm). Mass spectra data and high-resolution mass
measurements were performed on a VG-Analytical Autospec Q
mass spectrometer. Elemental analyses were performed on a 240 C
PerkineElmer C, H, N analyser. HPLC analyses were run on an
Agilent 1100 system equipped with a quaternary pump and
a multiple wavelength detector. Reversed-phase HPLC was per-
formed on a Kinetex C18, 2.6 mm (100  4.6 mm) column (Phe-
nomenex, Torrance, CA, USA). Chiral HPLC was performed on
a Kromasil 3-CelluCoat RP, 3 mm (150  4.6 mm) column (Akzo-
Nobel, Eka Chemicals, Bohus, Sweden) and on a Chirex (S)-tert-
leucine and 3,5-dinitroaniline, 5 mm (150  4.6 mm) column
(Phenomenex, Torrance, CA, USA). The purity of all new compounds
was determined by elemental analyses and some compounds also
additionally by HPLC. Analyses indicated by the symbols of the
elements were within 0.4% of the theoretical values.
5.6. Experimental procedures
5.6.1. Synthesis of diethyl 4-aminocyclohexane-1,3-dicarboxylate
(12d)
Step 1. Diethyl 4-oxocyclohexane-1,3-dicarboxylate, racemate
(14).
Sodium was slowly added to a stirred solution of compound 13
(1.15 g, 4.00 mmol) in toluene (10 mL). After heating the mixture to
90 C, absolute EtOH (100 mL) was added, and the mixture reﬂuxed
for 8 h. After the reaction was complete, it was cooled and poured
into a mixture of ice and dilute HCl. The organic layer was then
collected, and the aqueous layer extractedwith toluene (215mL).
The combined toluene layers were washed with saturated aqueous
NaHCO3 (3  30 mL) and then H2O (2  30 mL), and dried over
Na2SO4 and ﬁltered. The solvent was evaporated under reduced
pressure to yield the pure product 14 as a yellow oil (852 mg, 88%).
[a]D20: þ0.8 (c 0.163, CH2Cl2); 1H NMR (300 MHz, CDCl3, mixture of
ketoeenol tautomers): d 1.21e1.36 (m, 6H, 2  CH2CH3), 1.63e1.88
(m, 1H, cyclohexyl-H), 1.95e2.62 (m, 6H, cyclohexyl-H), 2.68e2.93
and 12.22 (m and s, 1H, cyclohexyl-H and OH), 4.09e4.30 (m, 4H,
2 CH2CH3); HRMS (ESI)m/z calcd for C12H19O5 [MþH]þ 243.1232,
found 243.1235. Purity by HPLC >99%.
Step 2.
Method 1. (E/Z)-Diethyl 4-(hydroxyimino)cyclohexane-1,3-dicar-
boxylate, racemate (15) [37].
To a solution of 14 (689 mg, 2.85 mmol) in EtOH (7 mL),
hydroxylamine hydrochloride (285.2 mg, 4.10 mmol) in H2O (2 mL)
was added during continuous stirring. After 5 min, a solution of
Na2CO3 (217.3 mg, 2.05 mmol) in H2O (3 mL) was added drop-wise
and the mixture was stirred for an additional 1 h. After the reaction
was complete, the mixture was diluted with H2O, and extracted
with Et2O (3  15 mL). The combined organic extracts were dried
over Na2SO4, ﬁltered, and evaporated to dryness, yielding a yellowoil. The crude product was puriﬁed by column chromatography
(CH2Cl2/MeOH 1/15), to yield a colourless oil that formed a precip-
itate upon addition of hexane. Unstable white solid (265 mg, 32%);
mp: 62e64 C (lit. [37] 64e65 C); 1H NMR (300 MHz, CDCl3,
mixture of E- and Z-isomers): d 1.21e1.32 (m, 6H, 2  CH2CH3),
1.51e1.95 (m, 3H, cyclohexyl-H), 2.03e2.59 (m, 3H, cyclohexyl-H),
3.13e3.28 (m, 1H, cyclohexyl-H), 3.35e3.52 (m, 1H, cyclohexyl-H),
4.06e4.27 (m, 4H, 2 CH2CH3), 7.80 and 7.99 (br s, 1H, NOH, E- and
Z-isomer); HRMS (ESI) m/z calcd for C12H19NO5Na [M þ Na]þ
280.1174, found 280.1164.
Method 2. Diethyl 4-(benzylamino)cyclohexane-1,3-dicarbox-
ylate, racemate (16).
Na(OAc)BH3 (847 mg, 4.00 mmol) and AcOH (172 mg,
2.86 mmol) were consecutively added to a stirred solution of
compound 14 (692 mg, 2.86 mmol) and benzylamine (288 mg,
2.86 mmol) in 1,2-dichloroethane (10 mL). When the starting
synthone disappeared (monitored by TLC), saturated aqueous
NaHCO3 (10 mL) was added, and the mixture extracted with Et2O
(3  30 mL). The combined organic extracts were washed with
brine, dried over Na2SO4, and ﬁltered. The solvent was evaporated
under reduced pressure and the residue was puriﬁed by column
chromatography (EtOAc/hexane 1/3) to yield the pure product 16 as
awhite solid (686mg, 72%). Mp: 52.0e53.5 C; [a]D20:þ1.5 (c 0.149,
CH2Cl2); 1H NMR (300 MHz, CDCl3): d 1.21e1.30 (m, 6H,
2  CH2CH3), 1.32e1.45 (m, 1H, cyclohexyl-H), 1.71e1.87 (m, 2H,
cyclohexyl-H), 1.91e2.12 (m, 3H, cyclohexyl-H), 2.29e2.39 (m, 1H,
cyclohexyl-H), 2.47e2.57 (m, 1H, cyclohexyl-H), 3.30 (q, J ¼ 3.1 Hz,
1H, cyclohexyl-H), 3.66 and 3.84 (AB, JAB ¼ 13.3 Hz, 2H, NHCH2),
4.07e4.22 (m, 4H, 2  CH2CH3), 7.20e7.35 (m, 5H, Ar-H), resonance
for NH missing; HRMS (ESI) m/z calcd for C19H28NO4 [M þ H]þ
334.2018, found 334.2010; Anal. (C19H27NO4) C, H, N.
Step 3. Diethyl 4-aminocyclohexane-1,3-dicarboxylate, racemate
(12d).
Method 1. To a solution of the oxime 15 (252 mg, 0.98 mmol) in
i-PrOH (10 mL), Raney-Ni (25 mg) was added, and the mixture
was hydrogenated for 2 h under reﬂux. The catalyst was then
ﬁltered out and the ﬁltrate evaporated under reduced pressure.
The crude product was puriﬁed by column chromatography
(CH2Cl2/MeOH 20/1) to yield 12d as a yellow oil (138 mg, 58%).
The detailed spectroscopic data for the compound obtained
with Method 2 is described below.
Method 2. To a solution of compound 16 (382 mg, 1.15 mmol) in
EtOH (50 mL), 10% Pd/C (70 mg) was added, and the mixture was
hydrogenated for 48 h at 20 bar in a Parr hydrogenation apparatus.
The suspension was then ﬁltered through a pad of celite and
washed with EtOH (40 mL). The solvent was removed under
reduced pressure and the residue puriﬁed by column chromatog-
raphy (CH2Cl2/MeOH 9/1) to yield the pure product 12d as a yellow
oil (221 mg, 79%). [a]D20 :0 (c 0.028, CH2Cl2); 1H NMR (300 MHz,
CDCl3): d 1.21e1.31 (m, 6H, 2  CH2CH3), 1.58e1.87 (m, 4H,
cyclohexyl-H), 1.89e2.10 (m, 2H, cyclohexyl-H), 2.23e2.35 (m, 1H,
cyclohexyl-H), 2.44e2.55 (m, 1H, cyclohexyl-H), 3.53 (q, J ¼ 3.0 Hz,
1H, cyclohexyl-H), 4.08e4.26 (m, 4H, 2  CH2CH3), resonance for
NH2 missing; HRMS (ESI) m/z calcd for C12H22NO4 [M þ H]þ
244.1549, found 244.1558.
5.6.2. Synthesis of dimethyl 4-aminoisophthalate (12i)
Step 1. Method 1. 4-(benzylamino)isophthalic acid (18) [39].
A mixture of 4-bromoisophthalic acid (17) (1.23 g, 5.00 mmol),
benzylamine (1.03 g, 10.00 mmol), K2CO3 (691.1 mg, 5.00 mmol),
Cu powder (28.9mg, 0.46mmol), and Cu2O (32.5mg, 0.23mmol) in
2-ethoxyethanol (3 mL) was irradiated at 130 C (5 MW power) for
45 min in a sealed tube (10 mL pressure-rated reaction vial). The
mixture was cooled rapidly to room temperature, the solvent
removed under reduced pressure, and then H2O (30 mL) added to
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through a pad of celite. The ﬁltrate was acidiﬁed (pH 5) with 1 M
HCl to give a precipitate, which was dissolved in aqueous Na2CO3
(5%, 50 mL), and ﬁltrated through a pad of celite. The solution was
again acidiﬁed (pH 4) with 1 M HCl to provide the solid 18, which
was ﬁltered off, dried, and used in the next step without further
puriﬁcation. Pale brown solid (190 mg, 21%); 1H NMR (300 MHz,
DMSO-d6): d 4.54 (s, 2H, NHCH2), 6.75 (d, J ¼ 9.0 Hz, 1H, Ar-H),
7.31e7.37 (m, 5H, Ar-H), 7.82 (dd, J ¼ 8.9, 2.0 Hz, 1H, Ar-H), 8.44 (s,
1H, Ar-H), 8.75 (br s, 1H, NHCH2), 12.86 (br s, 2H, 2  COOH); HRMS
(ESI) m/z calcd for C15H12NO4 [MeH] 270.0766, found 270.0774.
Step 2. Method 1. Dimethyl 4-(benzylamino)isophthalate (19).
To an ice-cooled solution of 18 (425 mg, 1.57 mmol) in MeOH
(15 mL), SOCl2 (1.87 g, 15.70 mmol) was slowly added with
continuous stirring. The mixture was stirred at room temperature
for 2 days. After the reaction was complete (monitored by TLC), the
solvent was evaporated, and saturated aqueous NaHCO3 (20 mL)
was added to the residue. The aqueous phase was extracted with
EtOAc (3  20 mL), and the combined organic phases were washed
with brine (2  20 mL), dried over Na2SO4, ﬁltered, and removed
under reduced pressure. The resulting residue was puriﬁed by
column chromatography (EtOAc/hexane 1/3) to provide 19 as
a white solid (328 mg, 70%). Mp: 79.0e83.0 C; 1H NMR (300 MHz,
CDCl3): d 3.86 (s, 3H, CH3), 3.89 (s, 3H, CH3), 4.50 (d, J ¼ 5.6 Hz, 2H,
NHCH2), 6.65 (d, J ¼ 9.0 Hz, 1H, Ar-H), 7.29e7.39 (m, 5H, Ar-H), 7.94
(dd, J ¼ 8.9, 2.0 Hz, 1H, Ar-H), 8.64 (s, 1H, Ar-H), 8.69 (br s, 1H,
NHCH2); HRMS (ESI) m/z calcd for C17H18NO4 [M þ H]þ 300.1236,
found 300.1228; Anal. (C17H17NO4) C, H, N.
Step 3. Method 1. Dimethyl 4-aminoisophthalate (12i) [40].
To a solution of compound 19 (300 mg, 1.00 mmol) in MeOH
(15 mL), 10% Pd-C (30 mg) was added, and the mixture was
hydrogenated for 10 h at room temperature. The suspension was
then ﬁltered through a pad of celite and washed with MeOH
(20 mL). The solvent was evaporated under reduced pressure,
yielding the pure product 12i as a white solid (178 mg, 85%). Mp:
126.5e127.0 C (lit. [40] 127e128 C); 1H NMR (300 MHz, CDCl3):
d 3.87 (s, 3H, CH3), 3.89 (s, 3H, CH3), 6.20 (br s, 2H, NH2), 6.64 (d,
J ¼ 8.7 Hz, 1H, Ar-H), 7.90 (dd, J ¼ 8.7, 2.1 Hz, 1H, Ar-H), 8.58 (d,
J ¼ 2.1 Hz, 1H, Ar-H); HRMS (ESI)m/z calcd for C10H12NO4 [M þ H]þ
210.0766, found 210.0769.
5.6.3. Experimental procedure for the synthesis of 6-substituted
naphthalene-2-sulfonamides 31aei and 32aei
The target compoundswere prepared from sulfonyl chlorides 27
and 28 in two consecutive steps; these were synthesised from the
appropriate starting materials following literature procedures [34],
and from commercially available or synthesised aromatic or cyclic
aliphatic amines 12aei.
Step 1. Formation of protected 6-substituted naphthalene-2-
sulfonamides (29aei, 30aei).
Method 1 (29aee, 30aee, and 29g, 30g).
Sulfonyl chloride 27 or 28 (1.00 mmol) was dissolved in CH2Cl2
(5 mL) and slowly added to a solution of the appropriate amine
12aee or 12g (1.20 mmol) in CH2Cl2 (5 mL), followed by the addi-
tion of Et3N (2.50 mmol) after 10 min. The reaction mixture was
stirred at room temperature for 24 h, or until the reaction was
complete (monitored by TLC), quenched with 1 M HCl (15 mL), and
extracted with CH2Cl2 (3  30 mL). The combined organic layers
were washed with brine, dried over Na2SO4, ﬁltered, and evapo-
rated under reduced pressure, giving a residue that was puriﬁed by
column chromatography, to obtain compounds 29aee, 30aee, and
29g, 30g.
Method 2 (29f, 30f).
Sulfonyl chloride 27 or 28 (1.00 mmol) was dissolved in dry THF
(5 mL) and slowly added to a solution of amine 12f (1.20 mmol) indry THF (5 mL), followed by the addition of Et3N (2.50 mmol) after
10 min. After the reaction was complete (monitored by TLC), the
solvent was removed under reduced pressure, and then 1 M HCl
(15 mL) was added and the product extracted with CH2Cl2
(3 30 mL). The combined organic phases were washed with brine
(2  30 mL), dried over Na2SO4, ﬁltered, and evaporated under
reduced pressure. The resulting crude products were puriﬁed by
column chromatography, to yield compounds 29f and 30f.
Method 3 (29h, 30h).
Sulfonyl chloride 27 or 28 (1.00 mmol) was slowly added to
a solution of 12h (1.20 mmol) in EtOH (10 mL), followed by the
addition of Et3N (2.50 mmol) after 10 min. The reaction mixture
was stirred for 2 days at 55 C. After the reaction was complete
(monitored by TLC), the solvent was removed under reduced
pressure, and then 1 M HCl (15 mL) was added and the product
extracted with CH2Cl2 (3  30 mL). The combined organic phases
were washed with brine (2  30 mL), dried over Na2SO4, ﬁltered
and evaporated under reduced pressure. The resulting crude
products were puriﬁed by column chromatography, to yield
compounds 29a, 30a and 29h, 30h.
Method 4 (29i, 30i).
Sulfonyl chloride 27 or 28 (1.00 mmol) was dissolved in CH2Cl2
(5 mL) and slowly added to a solution of amine 12i (1.20 mmol) in
CH2Cl2 (5 mL), followed by the addition of Py (2.50 mmol) after
10 min. The reaction mixture was stirred for 2 days at 50 C. After
the reactionwas complete (monitored by TLC), 1 M HCl (15mL) was
added and the product extracted with CH2Cl2 (3  30 mL). The
combined organic phases were washed with brine (2  30 mL),
dried over Na2SO4, ﬁltered, and evaporated under reduced pres-
sure. The resulting crude products were puriﬁed by column chro-
matography, to yield compounds 29i and 30i.
5.6.3.1. Methyl 1-(6-butoxynaphthalen-2-ylsulfonyl)piperidine-4-carbox-
ylate (29a). Puriﬁcation on SiO2 (EtOAc/hexane 1/3) gave 279mg (76%)
of awhite solid. Mp: 132.0e133.5 C; 1H NMR (300MHz, CDCl3): d 1.01
(t, J¼ 7.4Hz, 3H, CH2CH3),1.48e1.62 (m, 2H, CH2CH3),1.75e1.91 (m, 4H,
OCH2CH2 and piperidyl-H), 1.92e2.02 (m, 2H, piperidyl-H), 2.18e2.29
(m, 1H, piperidyl-H), 2.52 (td, J ¼ 11.5, 2.8 Hz, 2H, piperidyl-H), 3.64 (s,
3H, CH3), 3.70 (dt, J¼ 11.8, 3.6Hz, 2H, piperidyl-H), 4.11 (t, J¼ 6.5Hz, 2H,
OCH2), 7.17 (d, J ¼ 2.4 Hz, 1H, Naph-H), 7.26 (dd, J ¼ 8.9, 2.4 Hz, 1H,
Naph-H), 7.69 (dd, J ¼ 8.6, 1.7 Hz, 1H, Naph-H), 7.81 (d, J ¼ 8.6 Hz, 1H,
Naph-H), 7.85 (d, J¼ 8.9 Hz, 1H, Naph-H), 8.23 (d, J¼ 1.7 Hz, 1H, Naph-
H); HRMS (ESI) m/z calcd for C21H28NO5S [M þ H]þ 406.1688, found
406.1674; Anal. (C21H27NO5S) C, H, N.
5.6.3.2. (1R,2S)-ethyl 2-(6-butoxynaphthalene-2-sulfonamido)cyclo-
hexanecarboxylate (29b). Puriﬁcation on SiO2 (EtOAc/hexane 1/3)
gave 358mg (83%) of a white solid. Mp: 79.5e81.0 C; [a]D20:þ20.8
(c 0.268, CH2Cl2); 1H NMR (300MHz, CDCl3): d 1.01 (t, J¼ 7.4 Hz, 3H,
CH2CH3), 1.12 (t, J¼ 7.1 Hz, 3H, OCH2CH3), 1.18e1.68 (m, 8H, CH2CH3
and cyclohexyl-H), 1.70e2.02 (m, 4H, OCH2CH2 and cyclohexyl-H),
2.62 (q, J ¼ 4.7 Hz, 1H, cyclohexyl-H), 3.48 (sym m, 1H, cyclohexyl-
H), 3.84e4.14 (m, 4H, OCH2 and OCH2CH3), 5.60 (d, J ¼ 8.7 Hz, 1H,
NH), 7.16 (d, J ¼ 2.3 Hz, 1H, Naph-H), 7.25 (dd, J ¼ 8.9, 2.3 Hz, 1H,
Naph-H), 7.74e7.81 (m, 2H, Naph-H), 7.83 (d, J ¼ 8.9 Hz, 1H, Naph-
H), 8.33 (d, J ¼ 1.6 Hz, 1H, Naph-H); HRMS (ESI) m/z calcd for
C23H32NO5S [M þ H]þ 434.2001, found 434.1989; Anal
(C23H31NO5S) C, H, N.
5.6.3.3. (1R,2R)-ethyl 2-(6-butoxynaphthalene-2-sulfonamido)cyclo-
hexanecarboxylate (29c). Puriﬁcation on SiO2 (EtOAc/hexane 1/3)
gave 305 mg (70%) of a white solid. Mp: 121.5e122.5 C;
[a]D20: þ10.5 (c 0.194, CH2Cl2); 1H NMR (300 MHz, CDCl3):
d 0.98e1.06 (m, 6H, CH2CH3 and OCH2CH3), 1.10e1.31 (m, 3H,
cyclohexyl-H), 1.43e1.71 (m, 5H, CH2CH3 and cyclohexyl-H),
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cyclohexyl-H), 2.22 (td, J ¼ 11.2, 3.8 Hz, 1H, cyclohexyl-H),
3.35e3.48 (m, 1H, cyclohexyl-H), 3.65e3.89 (m, 2H, OCH2CH3),
4.11 (t, J ¼ 6.5 Hz, 2H, OCH2), 4.64 (d, J ¼ 7.8 Hz, 1H, NH), 7.15 (d,
J ¼ 2.3 Hz, 1H, Naph-H), 7.25 (dd, J ¼ 8.9, 2.3 Hz, 1H, Naph-H),
7.72e7.81 (m, 2H, Naph-H), 7.84 (d, J ¼ 8.9 Hz, 1H, Naph-H),
8.32 (d, J ¼ 1.6 Hz, 1H, Naph-H); 13C NMR (100 MHz, CDCl3):
d 13.83, 13.89, 19.25, 24.04, 24.35, 28.46, 31.13, 33.74, 49.90, 54.26,
60.62, 67.88, 106.40, 120.63, 123.05, 127.27, 127.73, 127.97,
130.62, 135.36, 136.45, 159.33, 173.46; HRMS (ESI) m/z calcd
for C23H32NO5S [M þ H]þ 434.2001, found 434.2001; Anal.
(C23H31NO5S) C, H, N.
5.6.3.4. Diethyl 4-(6-butoxynaphthalene-2-sulfonamido)cyclohexane-
1,3-dicarboxylate, racemate (29d). Puriﬁcation on SiO2 (EtOAc/
hexane 1/3) gave 184 mg (59%) of a white solid. Mp: 98.0e99.0 C;
[a]D20: þ1.1 (c 0.169, CH2Cl2); 1H NMR (300 MHz, CDCl3): d 0.94 (t,
J ¼ 7.1 Hz, 3H, OCH2CH3), 1.01 (t, J ¼ 7.4 Hz, 3H, CH2CH3), 1.25 (t,
J ¼ 7.1 Hz, 3H, OCH2CH3), 1.33e1.45 (m, 1H, cyclohexyl-H), 1.48e1.61
(m, 2H, CH2CH3), 1.71e1.92 (m, 5H, OCH2CH2 and cyclohexyl-H),
1.94e2.05 (m, 1H, cyclohexyl-H), 2.08e2.34 (m, 2H, cyclohexyl-H),
2.47 (dt, J ¼ 12.3, 3.9 Hz, 1H, cyclohexyl-H), 3.55 (sym m, 1H,
cyclohexyl-H), 3.68e3.92 (m, 2H, OCH2CH3), 4.06e4.17 (m, 4H, OCH2
and OCH2CH3), 5.18 (d, J ¼ 6.0 Hz, 1H, NH), 7.15 (d, J ¼ 2.3 Hz, 1H,
Naph-H), 7.25 (dd, J ¼ 8.9, 2.3 Hz, 1H, Naph-H), 7.73e7.82 (m, 2H,
Naph-H), 7.84 (d, J ¼ 8.9 Hz, 1H, Naph-H), 8.32 (d, J ¼ 1.6 Hz, 1H,
Naph-H); HRMS (ESI) m/z calcd for C26H36NO7S [M þ H]þ 506.2212,
found 506.2227; Anal. (C26H35NO7S) C, H, N.
5.6.3.5. Methyl 2-(4-(6-butoxynaphthalene-2-sulfonamido)phenyl)
acetate (29e). Puriﬁcation on SiO2 (EtOAc/hexane 1/5) gave 86 mg
(87%) of a pale brown solid. Mp: 102.0e103.0 C; 1H NMR
(300 MHz, CDCl3): d 1.00 (t, J ¼ 7.4 Hz, 3H, CH2CH3), 1.46e1.59 (m,
2H, CH2CH3), 1.77e1.89 (m, 2H, OCH2CH2), 3.52 (s, 2H, CH2COO),
3.65 (s, 3H, CH3), 4.09 (t, J ¼ 6.5 Hz, 2H, OCH2), 6.52 (br s, 1H, NH),
6.99e7.05 (m, 2H, Ar-H), 7.09e7.15 (m, 3H, Ar-H), 7.22 (dd, J ¼ 8.9,
2.4 Hz, 1H, Ar-H), 7.67 (dd, J ¼ 8.6, 1.7 Hz, 1H, Ar-H), 7.71e7.79 (m,
2H, Ar-H), 8.24 (d, J ¼ 1.7 Hz, 1H, Ar-H); HRMS (ESI) m/z calcd for
C23H26NO5S [M þ H]þ 428.1532, found 428.1527; Anal.
(C23H25NO5S) C, H, N.
5.6.3.6. Methyl 2-(6-butoxynaphthalene-2-sulfonamido)-5-hydrox-
ybenzoate (29f). Puriﬁcation on SiO2 (EtOAc/hexane 3/5) gave
221 mg (77%) of a yellow solid. Mp: 127.0e129.0 C; 1H NMR
(300 MHz, DMSO-d6): d 0.96 (t, J ¼ 7.4 Hz, 3H, CH2CH3), 1.41e1.56
(m, 2H, CH2CH3), 1.77e1.89 (m, 2H, OCH2CH2), 3.65 (s, 3H, CH3), 4.15
(t, J ¼ 6.5 Hz, 2H, OCH2), 6.64 (d, J ¼ 9.0 Hz, 1H, Ar-H), 6.72 (s, 1H,
OH), 6.84 (dd, J ¼ 9.1, 2.9 Hz, 1H, Ar-H), 7.24 (d, J¼ 2.8 Hz, 1H, Ar-H),
7.32 (dd, J ¼ 9.0, 2.4 Hz, 1H, Ar-H), 7.51 (d, J ¼ 2.4 Hz, 1H, Ar-H), 7.76
(dd, J ¼ 8.7, 1.9 Hz, 1H, Ar-H), 8.04 (d, J ¼ 8.7 Hz, 1H, Ar-H), 8.10 (d,
J ¼ 9.0 Hz, 1H, Ar-H), 8.41 (d, J ¼ 1.8 Hz, 1H, Ar-H), 10.69 (br s, 1H,
NH); HRMS (ESI) m/z calcd for C22H24NO6S [M þ H]þ 430.1324,
found 430.1328; Anal. (C22H23NO6S) C, H, N.
5.6.3.7. Dimethyl 2-(6-butoxynaphthalene-2-sulfonamido)terephthalate
(29g). Puriﬁcation on SiO2 (EtOAc/hexane 1/3) gave 212 mg (45%) of
a white solid. Mp 125.5e126.5 C; 1H NMR (300 MHz, CDCl3) d 0.99 (t,
J ¼ 7.4 Hz, 3H, CH2CH3), 1.45e1.51 (m, 2H, CH2CH3), 1.77e1.91 (m, 2H,
OCH2CH2), 3.87 (s, 3H, CH3), 3.93 (s, 3H, CH3), 4.07 (t, J ¼ 6.5 Hz, 2H,
OCH2), 7.11 (d, J ¼ 2.4 Hz, 1H, Ar-H), 7.22 (dd, J ¼ 9.0, 2.4 Hz, 1H, Ar-H),
7.62 (dd, J ¼ 8.3, 1.5 Hz, 1H, Ar-H), 7.72e7.84 (m, 3H, Ar-H), 7.93 (d,
J¼ 8.3Hz,1H, Ar-H), 8.39 (d, J¼ 1.5Hz,1H, Ar-H), 8.41 (d, J¼ 1.5Hz,1H,
Ar-H), 10.63 (br s, 1H, NH); 13C NMR (100 MHz, CDCl3): d 13.80, 19.22,
31.07, 52.64, 52.74, 67.93, 106.36, 118.89, 119.75, 120.87, 122.84, 123.26,
127.13, 127.94, 129.04, 130.71, 131.19, 133.21, 135.19, 136.82, 140.52,159.67, 165.56, 167.63; HRMS (ESI) m/z calcd for C24H24NO7S [MeH]
470.1273, found 470.1268; Anal. (C24H25NO7S) C, H, N.
5.6.3.8. Dimethyl 5-(6-butoxynaphthalene-2-sulfonamido)isophthalate
(29h). Puriﬁcation on SiO2 (EtOAc/hexane 3/5) gave 283 mg (62%) of
a white solid. Mp: 187.0e188.0 C; 1H NMR (300 MHz, CDCl3): d 0.99
(t, J ¼ 7.4 Hz, 3H, CH2CH3), 1.45e1.54 (m, 2H, CH2CH3), 1.77e1.89 (m,
2H, OCH2CH2), 3.91 (s, 6H, 2  CH3), 3.93 (s, 3H, CH3), 4.07 (t,
J¼ 6.5 Hz, 2H, OCH2), 7.09 (d, J¼ 2.4 Hz,1H, Ar-H), 7.11 (br s, 1H, NH),
7.21 (dd, J ¼ 9.0, 2.4 Hz, 1H, Ar-H), 7.66e7.75 (m, 2H, Ar-H), 7.77 (d,
J ¼ 9.0 Hz, 1H, Ar-H), 7.98e8.02 (m, 2H, Ar-H), 8.32 (d, J ¼ 1.5 Hz, 1H,
Ar-H), 8.36 (dd, J ¼ 1.4, 1.4 Hz, 1H, Ar-H); HRMS (ESI) m/z calcd for
C24H26NO7S [M þ H]þ 472.1320, found 472.1433; Anal. (C24H25NO7S)
C, H, N.
5.6.3.9. Dimethyl 4-(6-butoxynaphthalene-2-sulfonamido)isophthalate
(29i). Puriﬁcation on SiO2 (EtOAc/hexane 3/5) gave 184 mg (62%) of
a white solid. Mp: 75.0e76.0 C; 1H NMR (300 MHz, CDCl3): d 0.99 (t,
J¼ 7.4 Hz, 3H, CH2CH3), 1.46e1.57 (m, 2H, CH2CH3), 1.77e1.88 (m, 2H,
OCH2CH2), 3.86 (s, 3H, CH3), 3.92 (s, 3H, CH3), 4.08 (t, J ¼ 6.5 Hz, 2H,
OCH2), 7.10 (d, J¼ 2.4 Hz,1H, Ar-H), 7.23 (dd, J¼ 9.0, 2.4 Hz,1H, Ar-H),
7.71e7.80 (m, 3H, Ar-H), 7.82 (d, J¼ 9.0 Hz,1H, Ar-H), 8.05 (dd, J¼ 8.7,
2.1 Hz, 1H, Ar-H), 8.41 (d, J ¼ 1.5 Hz, 1H, Ar-H), 8.58 (d, J ¼ 2.1 Hz, 1H,
Ar-H), 11.09 (br s, 1H, NH); HRMS (ESI) m/z calcd for C24H25NO7SNa
[M þ Na]þ 494.1249, found 494.1269; Anal. (C24H25NO7S) C, H, N.
5.6.3.10. Methyl 1-(6-(4-cyano-2-ﬂuorobenzyloxy)naphthalen-2-ylsul-
fonyl)piperidine-4-carboxylate (30a). Puriﬁcation on SiO2 (EtOAc/
hexane 1/1) gave 175 mg (66%) of a white solid. Mp: 173.5e175.0 C;
1H NMR (300 MHz, CDCl3): d 1.75e1.90 (m, 2H, piperidyl-H),
1.92e2.03 (m, 2H, piperidyl-H), 2.25 (sym m, 1H, piperidyl-H), 2.56
(td, J ¼ 11.7, 2.9 Hz, 2H, piperidyl-H), 3.64 (s, 3H, CH3), 3.69 (dt,
J¼ 12.0, 3.9Hz, 2H, piperidyl-H), 5.34 (s, 2H, OCH2), 7.27 (d, J¼ 2.7 Hz,
1H, Ar-H), 7.35 (dd, J ¼ 9.0, 2.7 Hz, 1H, Ar-H), 7.44 (dd, J ¼ 9.3, 1.5 Hz,
1H, Ar-H), 7.53 (dd, J ¼ 7.9, 1.0 Hz, 1H, Ar-H), 7.69e7.77 (m, 2H, Ar-H),
7.85 (d, J ¼ 9.0 Hz, 1H, Ar-H), 7.91 (d, J ¼ 9.3 Hz, 1H, Ar-H), 8.26 (d,
J ¼ 1.0 Hz, 1H, Ar-H); HRMS (ESI) m/z calcd for C25H24FN2O5S
[M þ H]þ 483.1390, found 483.1370; Anal. (C25H23FN2O5S) C, H, N.
5.6.3.11. (1R,2S)-ethyl 2-(6-(4-cyano-2-ﬂuorobenzyloxy)naphtha-
lene-2-sulfonamido)cyclohexanecarboxylate (30b). Puriﬁcation on
SiO2 (EtOAc/hexane 3/5) gave 279 mg (71%) of a white solid. Mp:
141.0e143.5 C; [a]D20: 6.6 (c 0.192, CH2Cl2); 1H NMR (300 MHz,
CDCl3): d 1.12 (t, J ¼ 7.1 Hz, 3H, OCH2CH3), 1.18e1.69 (m, 6H,
cyclohexyl-H), 1.71e2.02 (m, 2H, cyclohexyl-H), 2.63 (q, 1H,
J¼ 4.9 Hz, cyclohexyl-H), 3.49 (symm,1H, cyclohexyl-H), 3.84e4.14
(m, 2H, OCH2CH3), 5.32 (s, 2H, OCH2), 5.65 (d, J ¼ 8.9 Hz, 1H, NH),
7.25 (d, J ¼ 2.4 Hz, 1H, Ar-H), 7.33 (dd, J ¼ 8.7, 2.4 Hz, 1H, Ar-H), 7.43
(dd, J ¼ 9.2, 1.4 Hz, 1H, Ar-H), 7.52 (dd, J ¼ 7.9, 1.0 Hz, 1H, Ar-H),
7.70e7.85 (m, 3H, Ar-H), 7.90 (d, J ¼ 9.2 Hz, 1H, Ar-H), 8.36 (d,
J ¼ 1.0 Hz, 1H, Ar-H); HRMS (ESI) m/z calcd for C27H28FN2O5S
[M þ H]þ 511.1703, found 511.1699; Anal. (C27H27FN2O5S) C, H, N.
5.6.3.12. (1R,2R)-ethyl 2-(6-(4-cyano-2-ﬂuorobenzyloxy)naphtha-
lene-2-sulfonamido)cyclohexanecarboxylate (30c). Puriﬁcation on
SiO2 (EtOAc/hexane 3/5) gave 318 mg (81%) of a white solid. Mp:
145.0e147.5 C; [a]D20: þ7.52 (c 0.269, CH2Cl2); 1H NMR (300 MHz,
CDCl3): d 1.04 (t, J ¼ 7.1 Hz, 3H, OCH2CH3), 1.10e1.33 (m, 3H,
cyclohexyl-H), 1.39e1.71 (m, 3H, cyclohexyl-H), 1.81e1.93 (m, 1H,
cyclohexyl-H), 2.01e2.12 (m, 1H, cyclohexyl-H), 2.23 (td, J ¼ 11.2,
3.8 Hz, 1H, cyclohexyl-H), 3.35e3.49 (m, 1H, cyclohexyl-H),
3.64e3.91 (m, 2H, OCH2CH3), 5.32 (s, 2H, OCH2), 4.72 (d, J ¼ 7.8 Hz,
1H, NH), 7.25 (d, J ¼ 2.4 Hz, 1H, Ar-H), 7.33 (dd, J ¼ 8.8, 2.4 Hz, 1H,
Ar-H), 7.43 (dd, J ¼ 9.3, 1.5 Hz, 1H, Ar-H), 7.52 (dd, J ¼ 7.9, 1.0 Hz, 1H,
Ar-H), 7.70e7.86 (m, 3H, Ar-H), 7.90 (d, J¼ 9.3 Hz, 1H, Ar-H), 8.36 (d,
I. Sosic et al. / European Journal of Medicinal Chemistry 46 (2011) 2880e2894 2891J ¼ 1.0 Hz, 1H, Ar-H); 13C NMR (100 MHz, CDCl3): d 13.90, 24.03,
24.36, 28.49, 33.77, 49.87, 54.31, 60.60, 63.02 and 63.07 (1C,
3JF,C ¼ 4.4 Hz), 107.07, 113.27 and 113.36 (1C, 3JF,C ¼ 9.5 Hz), 117.32
and 117.35 (1C, 4JF,C¼ 2.8 Hz), 118.94 and 119.18 (1C, 2JF,C¼ 25.7 Hz),
120.15, 123.42, 127.81, 127.95, 127.98, 128.47 and 128.51 (1C,
3JF,C ¼ 5.1 Hz), 129.58 and 129.72 (1C, 2JF,C ¼ 15.4 Hz), 130.04 and
130.08 (1C, 4JF,C ¼ 3.7 Hz), 131.13, 136.11, 136.20, 157.98, 158.23 and
160.72 (1C, 1JF,C ¼ 250.8 Hz), 173.45; HRMS (ESI) m/z calcd for
C27H28FN2O5S [M þ H]þ 511.1703, found 511.1698; Anal.
(C27H27FN2O5S) C, H, N.
5.6.3.13. Diethyl 4-(6-(4-cyano-2-ﬂuorobenzyloxy)naphthalene-2-sul-
fonamido)cyclohexane-1,3-dicarboxylate, racemate (30d). Puriﬁcation
on SiO2 (EtOAc/hexane 3/5) gave 284 mg (49%) of a white solid. Mp:
152.0e153.0 C; [a]D20: þ0.6 (c 0.157, CH2Cl2); 1H NMR (300 MHz,
CDCl3): d 0.95 (t, J ¼ 7.1 Hz, 3H, OCH2CH3), 1.25 (t, J ¼ 7.1 Hz, 3H,
OCH2CH3), 1.34e1.47 (m, 1H, cyclohexyl-H), 1.70e1.92 (m, 3H, cyclo-
hexyl-H), 1.94e2.04 (m, 1H, cyclohexyl-H), 2.08e2.36 (m, 2H, cyclo-
hexyl-H), 2.48 (dt, J¼ 12.4, 3.8 Hz,1H, cyclohexyl-H), 3.58 (symm,1H,
cyclohexyl-H), 3.69e3.95 (m, 2H, OCH2CH3), 4.13 (q, J ¼ 7.1 Hz, 1H,
OCH2CH3), 5.22 (d, J ¼ 6.1 Hz, 1H, NH), 5.33 (s, 2H, OCH2), 7.25 (d,
J ¼ 2.4 Hz, 1H, Ar-H), 7.34 (dd, J ¼ 9.0, 2.4 Hz, 1H, Ar-H), 7.44 (dd,
J ¼ 9.3, 1.5 Hz, 1H, Ar-H), 7.52 (dd, J ¼ 8.1, 1.0 Hz, 1H, Ar-H), 7.70e7.86
(m, 3H, Ar-H), 7.91 (d, J ¼ 9.3 Hz,1H, Ar-H), 8.35 (d, J¼ 1.0 Hz,1H, Ar-
H); HRMS (ESI)m/z calcd for C30H32FN2O7S [Mþ H]þ 583.1914, found
583.1906; Anal. (C30H31FN2O7S) C, H, N.
5.6.3.14. Methyl 2-(4-(6-(4-cyano-2-ﬂuorobenzyloxy)naphthalene-
2-sulfonamido)phenyl)acetate (30e). Puriﬁcation on SiO2 (EtOAc/
hexane 1/1) gave 263 mg (67%) of a pale brown solid. Mp:
184.5e186.0 C; 1H NMR (300 MHz, DMSO-d6): d 3.52 (s, 2H,
CH2COO), 3.55 (s, 3H, CH3), 5.39 (s, 2H, OCH2), 7.02e7.10 (m, 4H, Ar-
H), 7.38 (dd, J ¼ 9.0, 2.4 Hz, 1H, Ar-H), 7.57 (d, J ¼ 2.4 Hz, 1H, Ar-H),
7.73 (dd, J ¼ 8.7, 1.8 Hz, 1H, Ar-H), 7.76e7.85 (m, 2H, Ar-H),
7.90e7.99 (m, 2H, Ar-H), 8.07 (d, J ¼ 9.0 Hz, 1H, Ar-H), 8.36 (d,
J ¼ 1.8 Hz, 1H, Ar-H), 10.28 (br s, 1H, NH); HRMS (ESI) m/z calcd for
C27H22FN2O5S [M þ H]þ 505.1233, found 505.1230; Anal.
(C27H21FN2O5S) C, H, N.
5.6.3.15. Methyl 2-(6-(4-cyano-2-ﬂuorobenzyloxy)naphthalene-2-
sulfonamido)-5-hydroxybenzoate (30f). Puriﬁcation on SiO2 (EtOAc/
hexane 3/5) gave 185 mg (69%) of a yellowish solid. Mp:
159.5e162.5 C; 1H NMR (300 MHz, DMSO-d6): d 3.64 (s, 3H, CH3),
5.44 (s, 2H, OCH2), 6.64 (d, J ¼ 9.0 Hz, 1H, Ar-H), 6.72 (s, 1H, OH),
6.85 (dd, J¼ 9.0, 2.9 Hz, 1H, Ar-H), 7.23 (d, J¼ 2.9 Hz, 1H, Ar-H), 7.45
(dd, J¼ 9.0, 2.5 Hz,1H, Ar-H), 7.69 (d, J¼ 2.5 Hz,1H, Ar-H), 7.76e7.89
(m, 3H, Ar-H), 7.95 (dd, J ¼ 9.9, 1.5 Hz, 1H, Ar-H), 8.08 (d, J ¼ 9.0 Hz,
1H, Ar-H), 8.16 (d, J¼ 9.0 Hz, 1H, Ar-H), 8.45 (d, J¼ 1.7 Hz, 1H, Ar-H),
10.92 (br s, 1H, NH); HRMS (ESI) m/z calcd for C26H20FN2O6S
[M þ H]þ 507.1026, found 507.1030; Anal. (C26H19FN2O6S) C, H, N.
5.6.3.16. Dimethyl 2-(6-(4-cyano-2-ﬂuorobenzyloxy)naphthalene-2-
sulfonamido)terephthalate (30g). Puriﬁcation on SiO2 (EtOAc/
hexane 3/5) gave 141 mg (37%) of a white solid. Mp:
180.5e183.0 C; 1H NMR (300 MHz, CDCl3): d 3.89 (s, 3H, CH3), 3.93
(s, 3H, CH3), 5.29 (s, 2H, OCH2), 7.19 (d, J¼ 2.4 Hz,1H, Ar-H), 7.31 (dd,
J¼ 9.0, 2.4 Hz, 1H, Ar-H), 7.42 (dd, J¼ 9.3, 1.5 Hz, 1H, Ar-H), 7.51 (dd,
J¼ 7.9,1.3 Hz,1H, Ar-H), 7.63 (dd, J¼ 8.4,1.5 Hz,1H, Ar-H), 7.67e7.85
(m, 3H, Ar-H), 7.88 (d, J ¼ 9.3 Hz, 1H, Ar-H), 7.94 (d, J ¼ 8.4 Hz, 1H,
Ar-H), 8.39 (d, J ¼ 1.3 Hz, 1H, Ar-H), 8.45 (d, J ¼ 1.5 Hz, 1H, Ar-H),
10.67 (br s, 1H, NH); HRMS (ESI) m/z calcd for C28H22FN2O7S
[M þ H]þ 549.1132, found 549.1136; Anal. (C28H21FN2O7S) C, H, N.
5.6.3.17. Dimethyl 5-(6-(4-cyano-2-ﬂuorobenzyloxy)naphthalene-2-
sulfonamido)isophthalate (30h). Puriﬁcation on SiO2 (EtOAc/hexane3/5) gave 399 mg (64%) of a white solid. Mp: 206.0e209.0 C; 1H
NMR (300 MHz, CDCl3): d 3.91 (s, 6H, 2  CH3), 5.30 (s, 2H, OCH2),
6.90 (br s, 1H, NH), 7.20 (d, J ¼ 2.4 Hz, 1H, Ar-H), 7.31 (dd, J ¼ 9.0,
2.4 Hz, 1H, Ar-H), 7.43 (dd, J ¼ 9.3, 1.4 Hz, 1H, Ar-H), 7.51 (dd, J¼ 7.8,
1.3 Hz, 1H, Ar-H), 7.65e7.77 (m, 3H, Ar-H), 7.85 (d, J¼ 9.3 Hz, 1H, Ar-
H), 7.97e8.00 (m, 2H, Ar-H), 8.35 (d, J ¼ 1.3 Hz, 1H, Ar-H), 8.36 (dd,
J ¼ 1.4, 1.4 Hz, 1H, Ar-H); HRMS (ESI) m/z calcd for C28H20FN2O7S
[MeH] 547.0975, found 547.0974; Anal. (C28H21FN2O7S) C, H, N.
5.6.3.18. Dimethyl 4-(6-(4-cyano-2-ﬂuorobenzyloxy)naphthalene-2-
sulfonamido)isophthalate (30i). Puriﬁcation on SiO2 (EtOAc/hexane
3/5) gave 284 mg (52%) of a white solid. Mp: 169.0e170.0 C; 1H
NMR (300MHz, CDCl3): d 3.87 (s, 3H, CH3), 3.93 (s, 3H, CH3), 5.30 (s,
2H, OCH2), 7.20 (d, J ¼ 2.4 Hz, 1H, Ar-H), 7.33 (dd, J ¼ 9.0, 2.4 Hz, 1H,
Ar-H), 7.42 (dd, J ¼ 9.3, 1.3 Hz, 1H, Ar-H), 7.51 (dd, J ¼ 7.8, 1.3 Hz, 1H,
Ar-H), 7.67e7.85 (m, 4H, Ar-H), 7.89 (d, J ¼ 9.0 Hz, 1H, Ar-H), 8.06
(dd, J ¼ 8.7, 2.1 Hz, 1H, Ar-H), 8.45 (d, J ¼ 1.5 Hz, 1H, Ar-H), 8.59 (d,
J¼ 2.1 Hz,1H, Ar-H), 11.10 (br s, 1H, NH); 13C NMR (100MHz, CDCl3):
d 52.27, 52.76, 63.06 and 63.10 (1C, 3JF,C¼ 4.4 Hz), 107.07, 113.35 and
113.44 (1C, 3JF,C ¼ 9.4 Hz), 114.69, 117.28 and 117.31 (1C,
4JF,C ¼ 2.8 Hz), 117.43, 118.97 and 119.21 (1C, 2JF,C ¼ 24.2 Hz), 120.50,
123.01, 124.12, 127.65, 128.41, 128.48 and 128.52 (1C, 3JF,C ¼ 5.1 Hz),
128.86, 129.41 and 129.55 (1C, 2JF,C ¼ 14.8 Hz), 130.00 and 130.04
(1C, 4JF,C ¼ 3.7 Hz), 131.27, 133.14, 134.10, 135.35, 136.59, 144.21,
158.22 and 160.71 (1C, 1JF,C ¼ 250.6 Hz), 158.38, 165.54, 167.89;
HRMS (ESI) m/z calcd for C28H20FN2O7S [MeH] 547.0975, found
547.0968; Anal. (C28H21FN2O7S) C, H, N.Step 2. Alkaline hydrolysis
Compounds 31aei were prepared using 1 M NaOH as a base,
while compounds 32aei were prepared using 2 M LiOH as a base.
To a stirred solution of the protected 6-substituted naphthalene-2-
sulfonamides 29aei, 30aei (0.25 mmol) in dioxane (2 mL), the
appropriate base (1.5 ml 1 M NaOH, or 0.75 mL 2 M LiOH) was
added, and the reaction mixture stirred until the starting material
had completely reacted (monitored by TLC). Dioxane was then
evaporated under reduced pressure, the residue diluted with H2O
(10 mL), and washed with EtOAc (2  10 mL). The aqueous phase
was acidiﬁed to pH 2 using 1 M HCl, and extracted with EtOAc
(3  10 mL). The combined organic extracts were washed with
brine, then dried over Na2SO4, ﬁltered, and evaporated to dryness
to provide pure compounds 31aei, and crude products 32aei
that were puriﬁed by column chromatography (CH2Cl2/MeOH/
AcOH 9/1/0.1) to yield pure compounds.
5.6.3.19. 1-(6-Butoxynaphthalen-2-ylsulfonyl)piperidine-4-carboxylic
acid (31a). White solid (121mg, 92%); mp: 178.0e180.0 C; 1H NMR
(300 MHz, DMSO-d6): d 0.96 (t, J ¼ 7.4 Hz, 3H, CH2CH3), 1.41e1.65
(m, 4H, CH2CH3 and piperidyl-H), 1.70e1.94 (m, 4H, OCH2CH2 and
piperidyl-H), 2.24 (sym m, 1H, piperidyl-H), 2.45 (td, J ¼ 11.1, 1.8 Hz,
2H, piperidyl-H), 3.52 (dt, J ¼ 11.7, 3.9 Hz, 2H, piperidyl-H), 4.14 (t,
J ¼ 6.5 Hz, 2H, OCH2), 7.31 (dd, J ¼ 9.0, 2.4 Hz, 1H, Naph-H), 7.47 (d,
J¼ 2.4 Hz,1H, Naph-H), 7.68 (dd, J¼ 8.7,1.6 Hz,1H, Naph-H), 8.00 (d,
J ¼ 8.7 Hz, 1H, Naph-H), 8.09 (d, J ¼ 9.0 Hz, 1H, Naph-H), 8.32 (d,
J¼ 1.6 Hz,1H, Naph-H), 12.24 (br s,1H, COOH); HRMS (ESI)m/z calcd
for C20H24NO5S [MeH] 390.1375, found 390.1389; Anal.
(C20H25NO5S) C, H, N.
5.6.3.20. (1R,2S)-2-(6-butoxynaphthalene-2-sulfonamido)cyclo-
hexanecarboxylic acid (31b). White solid (117 mg, 89%); mp:
175.0e176.0 C; [a]D20: þ9.3 (c 0.161, DMSO); 1H NMR (300 MHz,
DMSO-d6): d 0.96 (t, J ¼ 7.4 Hz, 3H, CH2CH3), 1.01e1.26 (m, 4H,
cyclohexyl-H), 1.33e1.57 (m, 6H, CH2CH3 and cyclohexyl-H),
1.68e1.84 (m, 3H, OCH2CH2 and cyclohexyl-H), 3.56e3.69 (m, 1H,
cyclohexyl-H), 4.13 (t, J ¼ 6.5 Hz, 2H, OCH2), 7.27 (dd, J ¼ 9.0, 2.4 Hz,
1H, Naph-H), 7.42 (d, J ¼ 2.4 Hz, 1H, Naph-H), 7.57 (br d, J ¼ 8.7 Hz,
1H, NH), 7.82 (dd, J¼ 8.7, 1.8 Hz, 1H, Naph-H), 7.94 (d, J¼ 8.7 Hz, 1H,
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Naph-H), 12.09 (br s, 1H, COOH); HRMS (ESI) m/z calcd for
C21H28NO5S [M þ H]þ 406.1688, found 406.1674; Anal.
(C21H27NO5S) C, H, N.
5.6.3.21. (1R,2R)-2-(6-butoxynaphthalene-2-sulfonamido)cyclo-
hexanecarboxylic acid (31c). White solid (85 mg, 91%); mp:
178.0e179.5 C; [a]D20: þ4.1 (c 0.231, DMSO); 1H NMR (300 MHz,
DMSO-d6): d 0.96 (t, J ¼ 7.4 Hz, 3H, CH2CH3), 0.99e1.16 (m, 3H,
cyclohexyl-H), 1.28e1.57 (m, 6H, CH2CH3 and cyclohexyl-H),
1.70e1.87 (m, 3H, OCH2CH2 and cyclohexyl-H), 2.17 (td, J ¼ 10.5,
3.6 Hz, 1H, cyclohexyl-H), 3.28e3.41 (m, 1H, cyclohexyl-H, overlaps
with water), 4.13 (t, J ¼ 6.5 Hz, 2H, OCH2), 7.27 (dd, J ¼ 9.0, 2.4 Hz,
1H, Naph-H), 7.42 (d, J ¼ 2.4 Hz, 1H, Naph-H), 7.70 (br d, J ¼ 8.9 Hz,
1H, NH), 7.74 (dd, J¼ 8.7, 1.8 Hz, 1H, Naph-H), 7.93 (d, J¼ 8.7 Hz, 1H,
Naph-H), 8.03 (d, J ¼ 9.0 Hz, 1H, Naph-H), 8.31 (d, J ¼ 1.8 Hz, 1H,
Naph-H), 12.08 (br s, 1H, COOH); 13C NMR (100 MHz, DMSO-d6):
d 13.64, 18.71, 23.65, 23.74, 28.17, 30.56, 31.62, 48.99, 53.23, 67.40,
106.68, 120.10, 122.84, 126.50, 126.77, 127.71, 130.67, 135.74, 137.19,
158.52, 174.74; HRMS (ESI) m/z calcd for C21H28NO5S [M þ H]þ
406.1688, found 406.1704; Anal. (C21H27NO5S) C, H, N.
5.6.3.22. 4-(6-Butoxynaphthalene-2-sulfonamido)cyclohexane-1,
3-dicarboxylic acid, racemate (31d). White solid (54 mg, 87%);
mp: 228.0e231.0 C; [a]D20: þ1.2 (c 0.115, DMSO); 1H NMR
(300 MHz, DMSO-d6): d 0.96 (t, J ¼ 7.4 Hz, 3H, CH2CH3), 1.14e1.27
(m, 2H, cyclohexyl-H), 1.33e1.56 (m, 4H, CH2CH3 and cyclohexyl-H),
1.68e1.87 (m, 4H, OCH2CH2 and cyclohexyl-H), 2.04e2.19 (m, 1H,
cyclohexyl-H), 2.45e2.52 (m, 1H, cyclohexyl-H, overlaps with
DMSO), 3.86e3.97 (m, 1H, cyclohexyl-H), 4.13 (t, J ¼ 6.5 Hz, 2H,
OCH2), 7.27 (dd, J ¼ 9.0, 2.4 Hz, 1H, Naph-H), 7.42 (d, J ¼ 2.4 Hz, 1H,
Naph-H), 7.70 (br d, J ¼ 9.0 Hz, 1H, NH), 7.81 (dd, J ¼ 8.7, 1.8 Hz, 1H,
Naph-H), 7.93 (d, J ¼ 8.7 Hz, 1H, Naph-H), 8.02 (d, J ¼ 9.0 Hz, 1H,
Naph-H), 8.31 (d, J ¼ 1.8 Hz, 1H, Naph-H), 12.06 (br s, 2H,
2  COOH); HRMS (ESI) m/z calcd for C22H28NO7S [M þ H]þ
450.1586, found 450.1585; Anal. (C22H27NO7S) C, H, N.
5.6.3.23. 2-(4-(6-Butoxynaphthalene-2-sulfonamido)phenyl)acetic acid
(31e). White solid (70 mg, 91%); mp: 192.0e193.0 C; 1H NMR
(300 MHz, DMSO-d6): d 0.95 (t, J¼ 7.4 Hz, 3H, CH2CH3), 1.39e1.54 (m,
2H, CH2CH3), 1.70e1.82 (m, 2H, OCH2CH2), 3.40 (s, 2H, CH2COO), 4.11
(t, J ¼ 6.5 Hz, 2H, OCH2), 7.00e7.11 (m, 4H, Ar-H), 7.26 (dd, J ¼ 9.0,
2.4 Hz, 1H, Ar-H), 7.39 (d, J¼ 2.4 Hz, 1H, Ar-H), 7.70 (dd, J¼ 8.7, 1.8 Hz,
1H, Ar-H), 7.92 (d, J ¼ 8.7 Hz, 1H, Ar-H), 8.00 (d, J ¼ 9.0 Hz, 1H, Ar-H),
8.32 (d, J ¼ 1.8 Hz, 1H, Ar-H), 10.23 (br s, 1H, NH), 12.18 (br s, 1H,
COOH); HRMS (ESI) m/z calcd for C22H24NO5S [M þ H]þ 414.1375,
found 414.1358; Anal. (C22H23NO5S) C, H, N.
5.6.3.24. 2-(6-Butoxynaphthalene-2-sulfonamido)-5-hydroxybenzoic
acid (31f). Pale brown solid (116 mg, 84%); mp: 196.0e198.0 C; 1H
NMR (300 MHz, DMSO-d6): d 0.94 (t, J ¼ 7.4 Hz, 3H, CH2CH3),
1.39e1.53 (m, 2H, CH2CH3), 1.69e1.82 (m, 2H, OCH2CH2), 4.10 (t,
J ¼ 6.5 Hz, 2H, OCH2), 6.95 (dd, J ¼ 9.0, 3.0 Hz, 1H, Ar-H), 7.16 (d,
J ¼ 3.0 Hz, 1H, Ar-H), 7.26 (dd, J ¼ 9.0, 2.4 Hz, 1H, Ar-H), 7.36e7.44
(m, 2H, Ar-H), 7.55 (dd, J ¼ 8.7, 1.8 Hz, 1H, Ar-H), 7.87 (d, J ¼ 8.7 Hz,
1H, Ar-H), 8.00 (d, J¼ 9.0 Hz,1H, Ar-H), 8.30 (d, J¼ 1.8 Hz,1H, Ar-H),
9.61 (s, 1H, OH), 10.44 (br s, 1H, NH), 13.56 (br s, 1H, COOH); HRMS
(ESI) m/z calcd for C21H20NO6S [MeH] 414.1011, found 414.1013;
Anal. (C21H21NO6S) C, H, N.
5.6.3.25. 2-(6-Butoxynaphthalene-2-sulfonamido)terephthalic acid
(31g). White solid (149 mg, 87%); mp: 233.0e234.0 C; 1H NMR
(300 MHz, DMSO-d6): d 0.94 (t, J ¼ 7.4 Hz, 3H, CH2CH3), 1.39e1.53
(m, 2H, CH2CH3),1.68e1.81 (m, 2H, OCH2CH2), 4.10 (t, J¼ 6.5 Hz, 2H,
OCH2), 7.28 (dd, J ¼ 9.0, 2.4 Hz, 1H, Ar-H), 7.40 (d, J ¼ 2.4 Hz, 1H, Ar-H), 7.59 (dd, J ¼ 8.1, 1.5 Hz, 1H, Ar-H), 7.68 (dd, J ¼ 8.7, 1.8 Hz, 1H,
Ar-H), 7.90e7.93 (m, 2H, Ar-H), 8.03 (d, J¼ 9.0 Hz, 1H, Ar-H), 8.11 (d,
J ¼ 1.5 Hz, 1H, Ar-H), 8.44 (d, J ¼ 1.8 Hz, 1H, Ar-H), 11.14 (br s, 1H,
NH), 13.20 (br s, 2H, 2  COOH); 13C NMR (100 MHz, DMSO-d6):
d 13.61, 18.67, 30.48, 67.51, 106.71, 119.17, 120.39, 120.68, 122.19,
123.59, 126.65, 128.27, 128.35,130.87, 131.80, 132.64, 135.50, 136.44,
139.67, 159.17, 165.91, 169.03; HRMS (ESI)m/z calcd for C22H20NO7S
[MeH] 442.0960, found 442.0962; Anal. (C22H21NO7S) C, H, N.
5.6.3.26. 5-(6-Butoxynaphthalene-2-sulfonamido)isophthalic acid
(31h). White solid (96 mg, 98%); mp: 233.5e235.0 C; 1H NMR
(300 MHz, DMSO-d6): d 0.94 (t, J ¼ 7.4 Hz, 3H, CH2CH3), 1.39e1.52
(m, 2H, CH2CH3), 1.68e1.81 (m, 2H, OCH2CH2), 4.10 (t, J ¼ 6.5 Hz,
2H, OCH2), 7.26 (dd, J ¼ 9.0, 2.4 Hz, 1H, Ar-H), 7.39 (d, J ¼ 2.4 Hz,
1H, Ar-H), 7.69 (dd, J¼ 8.7, 1.8 Hz, 1H, Ar-H), 7.90e7.97 (m, 3H, Ar-
H), 8.02 (d, J¼ 9.0 Hz, 1H, Ar-H), 8.07 (dd, J ¼ 1.5, 1.5 Hz, 1H, Ar-H),
8.35 (d, J ¼ 1.8 Hz, 1H, Ar-H), 10.75 (br s, 1H, NH), 13.23 (br s, 2H,
2  COOH); HRMS (ESI) m/z calcd for C22H20NO7S [MeH]
442.0960, found 442.0968; Anal. (C22H21NO7S) C, H, N.
5.6.3.27. 4-(6-Butoxynaphthalene-2-sulfonamido)isophthalic acid
(31i). White solid (102 mg, 86%); mp: 243.0e244.0 C; 1H NMR
(300 MHz, DMSO-d6): d 0.93 (t, J ¼ 7.4 Hz, 3H, CH2CH3), 1.38e1.52
(m, 2H, CH2CH3), 1.69e1.81 (m, 2H, OCH2CH2), 4.10 (t, J ¼ 6.5 Hz,
2H, OCH2), 7.29 (dd, J ¼ 9.0, 2.4 Hz, 1H, Ar-H), 7.41 (d, J ¼ 2.4 Hz,
1H, Ar-H), 7.66 (d, J ¼ 8.7 Hz, 1H, Ar-H), 7.77 (dd, J ¼ 8.7, 1.8 Hz, 1H,
Ar-H), 7.95 (d, J¼ 8.7 Hz, 1H, Ar-H), 8.02 (dd, J¼ 8.7, 2.1 Hz, 1H, Ar-
H), 8.08 (d, J ¼ 9.0 Hz, 1H, Ar-H), 8.43 (d, J ¼ 2.1 Hz, 1H, Ar-H), 8.58
(d, J ¼ 1.8 Hz, 1H, Ar-H), 11.55 (br s, 1H, NH), 12.89 (br s, 2H,
2  COOH); HRMS (ESI) m/z calcd for C22H21NO7SNa [M þ Na]þ
466.0936, found 466.0932; Anal. (C22H21NO7S) C, H, N.
5.6.3.28. 1-(6-(4-Cyano-2-ﬂuorobenzyloxy)naphthalen-2-ylsulfonyl)
piperidine-4-carboxylic acid (32a). White solid (38 mg, 65%); mp:
217.0e218.0 C; 1H NMR (300 MHz, DMSO-d6): d 1.47e1.65 (m, 2H,
piperidyl-H), 1.80e1.94 (m, 2H, piperidyl-H), 2.17e2.31 (m, 1H,
piperidyl-H), 2.48 (td, J ¼ 11.1, 1.8 Hz, 2H, piperidyl-H), 3.52 (dt,
J¼ 11.8, 3.9 Hz, 2H, piperidyl-H), 5.43 (s, 2H, OCH2), 7.43 (dd, J¼ 9.0,
2.4 Hz, 1H, Ar-H), 7.65 (d, J ¼ 2.4 Hz, 1H, Ar-H), 7.71 (dd, J ¼ 8.7,
1.8 Hz, 1H, Ar-H), 7.81e7.88 (m, 2H, Ar-H), 7.95 (dd, J ¼ 9.9, 1.2 Hz,
1H, Ar-H), 8.04 (d, J¼ 8.7 Hz,1H, Ar-H), 8.16 (d, J¼ 9.0 Hz, 1H, Ar-H),
8.36 (d, J¼ 1.2 Hz, 1H, Ar-H), 12.22 (br s, 1H, COOH); HRMS (ESI)m/z
calcd for C24H20FN2O5S [MeH] 467.1077, found 467.1068; Anal.
(C24H21FN2O5S) C, H, N.
5.6.3.29. (1R,2S)-2-(6-(4-cyano-2-ﬂuorobenzyloxy)naphthalene-2-sul-
fonamido)cyclohexanecarboxylic acid (32b). White solid (95mg, 67%);
mp: 187.0e189.0 C; [a]D20: þ25.8 (c 0.149, DMSO); 1H NMR
(300 MHz, DMSO-d6): d 1.05e1.31 (m, 3H, cyclohexyl-H), 1.37e1.62
(m, 4H, cyclohexyl-H), 1.74e1.70 (m,1H, cyclohexyl-H), 2.47e2.55 (m,
1H, cyclohexyl-H), 3.60e3.75 (m, 1H, cyclohexyl-H), 5.47 (s, 2H,
OCH2), 7.45 (dd, J¼ 9.0, 2.1 Hz,1H, Ar-H), 7.65 (d, J¼ 2.1 Hz,1H, Ar-H),
7.80e7.94 (m, 3H, Ar-H), 7.97e8.06 (m, 2H, Ar-H), 8.14 (d, J ¼ 9.0 Hz,
1H, Ar-H), 8.43 (d, J ¼ 1.2 Hz, 1H, Ar-H), resonance for NH missing,
12.09 (br s, 1H, COOH); HRMS (ESI) m/z calcd for C25H22FN2O5S
[MeH] 481.1233, found 481.1220; Anal. (C25H23FN2O5S) C, H, N.
5.6.3.30. (1R,2R)-2-(6-(4-cyano-2-ﬂuorobenzyloxy)naphthalene-2-
sulfonamido)cyclohexanecarboxylic acid (32c). White solid (92mg,
65%); mp: 212.0e214.5 C; [a]D20: þ13.9 (c 0.024, DMSO); 1H NMR
(300 MHz, DMSO-d6): d 0.91e1.19 (m, 3H, cyclohexyl-H),
1.28e1.59 (m, 4H, cyclohexyl-H), 1.73e1.86 (m, 1H, cyclohexyl-H),
2.17 (td, J ¼ 10.4, 3.6, 1H, cyclohexyl-H), 3.27e3.39 (m, 1H, cyclo-
hexyl-H, overlaps with water), 5.41 (s, 2H, OCH2), 7.39 (dd, J ¼ 9.0,
2.1 Hz, 1H, Ar-H), 7.59 (d, J ¼ 2.1 Hz, 1H, Ar-H), 7.74e7.89 (m, 3H,
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(d, J ¼ 1.2 Hz, 1H, Ar-H), resonance for NH missing, 12.08 (br s, 1H,
COOH); 13C NMR (100 MHz, DMSO-d6): d 23.57, 23.67, 28.18, 31.67,
48.95, 53.28, 63.19 and 63.23 (1C, 3JF,C¼ 4.4 Hz), 107.42, 112.40 and
112.50 (1C, 3JF,C ¼ 10.3 Hz), 117.49 and 117.51 (1C, 4JF,C ¼ 2.7 Hz),
119.26 and 119.51 (1C, 2JF,C ¼ 25.7 Hz), 119.89, 123.04, 126.53,
127.18, 127.88, 128.95 and 128.99 (1C, 3JF,C ¼ 5.1 Hz), 129.70 and
129.84 (1C, 2JF,C ¼ 15.4 Hz), 130.96, 131.04 and 131.09 (1C,
4JF,C ¼ 3.7 Hz), 135.52, 137.64, 157.60, 158.28 and 160.75 (1C,
1JF,C ¼ 249.0 Hz), 174.78; HRMS (ESI) m/z calcd for C25H22FN2O5S
[MeH] 481.1233, found 481.1246; Anal. (C25H23FN2O5S) C, H, N.
5.6.3.31. 4-(6-(4-Cyano-2-ﬂuorobenzyloxy)naphthalene-2-sulfona-
mido)cyclohexane-1,3-dicarboxylic acid, racemate (32d). White
solid (64 mg, 64%); mp: 238.0e240.5 C; [a]D20: þ1.3 (c 0.079,
DMSO); 1H NMR (300 MHz, DMSO-d6): d 1.20e1.31 (m, 2H,
cyclohexyl-H), 1.34e1.58 (m, 2H, cyclohexyl-H), 1.67e1.86 (m, 2H,
cyclohexyl-H), 2.05e2.18 (m, 1H, cyclohexyl-H), 2.46e2.52 (m,
1H, cyclohexyl-H, overlaps with DMSO), 3.84e3.94 (m, 1H,
cyclohexyl-H), 5.41 (s, 2H, OCH2), 7.39 (dd, J ¼ 9.0, 2.0 Hz, 1H, Ar-
H), 7.60 (d, J ¼ 2.0 Hz, 1H, Ar-H), 7.75e7.88 (m, 3H, Ar-H),
7.92e8.01 (m, 2H, Ar-H), 8.08 (d, J ¼ 9.0 Hz, 1H, Ar-H), 8.35 (d,
J ¼ 1.1 Hz, 1H, Ar-H), resonance for NH missing, 12.05 (br s, 2H,
2  COOH); HRMS (ESI) m/z calcd for C26H24FN2O7S [M þ H]þ
527.1288, found 527.1271; Anal. (C26H23FN2O7S) C, H, N.
5.6.3.32. 2-(4-(6-(4-Cyano-2-ﬂuorobenzyloxy)naphthalene-2-sulfona-
mido)phenyl)acetic acid (32e). White solid (82 mg, 84%); mp:
187.0e190.0 C; 1H NMR (300 MHz, DMSO-d6): d 3.10 (s, 2H,
CH2COO), 5.38 (s, 2H, OCH2), 6.85e6.91 (m, 2H, Ar-H), 6.92e6.98 (m,
2H, Ar-H), 7.33 (dd, J ¼ 9.0, 2.4 Hz, 1H, Ar-H), 7.52 (d, J ¼ 2.4 Hz, 1H,
Ar-H), 7.69e7.86 (m, 3H, Ar-H), 7.87e8.96 (m, 2H, Ar-H), 8.02 (d,
J¼ 9.0 Hz,1H, Ar-H), 8.28 (d, J¼ 1.1 Hz,1H, Ar-H),10.25 (br s,1H, NH),
12.16 (br s, 1H, COOH); HRMS (ESI) m/z calcd for C26H18FN2O5S
[MeH] 489.0920, found 489.0925; Anal. (C26H19FN2O5S) C, H, N.
5.6.3.33. 2-(6-(4-Cyano-2-ﬂuorobenzyloxy)naphthalene-2-sulfona-
mido)-5-hydroxybenzoic acid (32f). White solid (78 mg, 59%); mp:
216.0e217.0 C; 1H NMR (300 MHz, DMSO-d6): d 5.39 (s, 2H, OCH2),
6.95 (dd, J ¼ 9.0, 3.0 Hz, 1H, Ar-H), 7.16 (d, J ¼ 3.0 Hz, 1H, Ar-H),
7.35e7.44 (m, 2H, Ar-H), 7.54e7.61 (m, 2H, Ar-H), 7.76 (dd, J ¼ 8.0,
1.4 Hz,1H, Ar-H), 7.80 (d, J¼ 8.0 Hz, 1H, Ar-H), 7.88e7.96 (m, 2H, Ar-
H), 8.06 (d, J¼ 9.0 Hz,1H, Ar-H), 8.33 (d, J¼ 1.4 Hz,1H, Ar-H), 9.62 (s,
1H, OH), 10.45 (br s, 1H, NH), 13.67 (br s, 1H, COOH); HRMS (ESI)m/z
calcd for C25H16FN2O6S [MeH] 491.0713, found 491.0701; Anal.
(C25H17FN2O6S) C, H, N.
5.6.3.34. 2-(6-(4-Cyano-2-ﬂuorobenzyloxy)naphthalene-2-sulfona-
mido)terephthalic acid (32g). White solid (35 mg, 59%); mp:
244.0e245.0 C; 1H NMR (300 MHz, DMSO-d6): d 5.39 (s, 2H,
OCH2), 7.38 (dd, J ¼ 9.0, 2.4 Hz, 1H, Ar-H), 7.52 (dd, J ¼ 8.1, 1.4 Hz,
1H, Ar-H), 7.57 (d, J ¼ 2.4 Hz, 1H, Ar-H), 7.70 (dd, J ¼ 8.7, 1.8 Hz,
1H, Ar-H), 7.73e7.85 (m, 2H, Ar-H), 7.90e7.98 (m, 3H, Ar-H),
8.05e8.11 (m, 2H, Ar-H), 8.44 (d, J ¼ 1.4 Hz, 1H, Ar-H), 10.95 (br s,
1H, NH), 13.20 (br s, 2H, 2  COOH); HRMS (ESI) m/z calcd
for C26H16FN2O7S [MeH] 519.0662, found 519.0646; Anal.
(C26H17FN2O7S) C, H, N.
5.6.3.35. 5-(6-(4-Cyano-2-ﬂuorobenzyloxy)naphthalene-2-sulfona-
mido)isophthalic acid (32h). White solid (32 mg, 56%); mp:
262.0e264.0 C; 1H NMR (300 MHz, DMSO-d6): d 5.39 (s, 2H,
OCH2), 7.38 (dd, J¼ 9.0, 2.4 Hz, 1H, Ar-H), 7.57 (d, J¼ 2.4 Hz, 1H, Ar-
H), 7.70e7.85 (m, 3H, Ar-H), 7.88e7.95 (m, 3H, Ar-H), 7.97 (d,
J ¼ 9.0 Hz, 1H, Ar-H), 8.05e8.11 (m, 2H, Ar-H), 8.35 (d, J ¼ 1.4 Hz,
1H, Ar-H), 10.80 (br s, 1H, NH), 12.83 (br s, 2H, 2  COOH); HRMS(ESI) m/z calcd for C26H17FN2O7SNa [M þ Na]þ 543.0638, found
543.0641; Anal. (C26H17FN2O7S) C, H, N.
5.6.3.36. 4-(6-(4-Cyano-2-ﬂuorobenzyloxy)naphthalene-2-sulfona-
mido)isophthalic acid (32i). White solid (62 mg, 68%); mp:
258.0e260.5 C; 1H NMR (300 MHz, DMSO-d6): d 5.37 (s, 2H,
OCH2), 7.34 (dd, J¼ 9.0, 2.4 Hz, 1H, Ar-H), 7.40 (d, J¼ 8.7 Hz, 1H, Ar-
H), 7.53 (d, J ¼ 2.4 Hz, 1H, Ar-H), 7.67e7.84 (m, 4H, Ar-H), 7.88 (d,
J ¼ 9.0 Hz, 1H, Ar-H), 7.92 (dd, J ¼ 9.1, 1.5 Hz, 1H, Ar-H), 8.07 (d,
J ¼ 9.0 Hz, 1H, Ar-H), 8.39e8.44 (m, 2H, Ar-H), 11.03 (br s, 1H, NH),
12.12 (br s, 2H, 2  COOH); 13C NMR (100 MHz, DMSO-d6): d 63.23
and 63.26 (1C, 3JF,C ¼ 4.4 Hz), 107.44, 112.39 and 112.49 (1C,
3JF,C ¼ 9.9 Hz), 117.03, 117.48 and 117.50 (1C, 4JF,C ¼ 2.5 Hz), 119.24
and 119.49 (1C, 2JF,C ¼ 24.9 Hz), 120.23, 122.68, 123.36, 127.11,
128.04,128.10,128.32,128.93 and 128.97 (1C, 3JF,C¼ 5.1 Hz), 129.58
and 129.73 (1C, 2JF,C ¼ 15.4 Hz), 131.01 and 131.06 (1C,
4JF,C ¼ 3.7 Hz), 131.13, 132.73, 134.27, 134.48, 135.98, 145.57, 158.00,
158.25 and 160.73 (1C, 1JF,C ¼ 249.1 Hz), 166.17, 169.97; HRMS (ESI)
m/z calcd for C26H16FN2O7S [MeH] 519.0662, found 519.0654;
Anal. (C26H17FN2O7S) C, H, N.
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